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Title of abstract:      Histopathological study of myelofibrosis (PMF) and essential 
thrombocythaemia(ET)  and correlation with  clinical and laboratory  features . 
Department:   General   Pathology  
Name of the candidate:  H. Pradeep 
Degree and subject:  MD (PATHOLOGY) 
Name of the guide:   Vivi   Srivastava 
AIM: 1) To describe the bone marrow morphology in primary myelofibrosis and essential 
thrombocythaemia. 
2) To develop a scoring system for the diagnosis of these conditions based the various histological 
parameters seen in bone marrow trephine biopsies in these groups of patients. 
3) To determine whether such a scoring system reliably distinguishes between ET and prefibrotic 
phase of PMF. 
4) To compare the blood and bone marrow findings in patients with and without JAK2V617 
mutations. 
 
Methods:  This was a  study done  on retrieved   bone marrow trephine biopsies in Department of 
General Pathology, Christian Medical College, Vellore .  134 cases were included in the study, which 
included   27 cases of ET ,  107 cases of  PMF , including 13 cases of prefibrotic phase of PMF  and  
correlated with  relevant laboratory  and clinical parameters . 
Parameters evaluated 
The histomorphological features of all  cases was studied in detail with a score applied for 
each histomorphological parameter with a maximum score of 21.  
Relevant statistical analysis for Categorical variables and continuous variables were done 
using   chi square test and fisher t test. 
Results  
All cases of ET had a total score of <10 and scores of prefibrotic MF ranged from 12-17 in 
our 21 point scoring system thus allowing a distinction between them. JAK2 positivity did 
have a influence on certain laboratory and histomorphological parameters such JAK2V617 
positive cases of PMF had a higher haemoglobin and total leukocyte count at presentation. 
On histopathology hyperchromatic dysplastic nuclei and small clusters were found more 
commonly in JAK2V617 positive MF. JAK2WT ET had a higher platelet count at diagnosis and 
also large clusters being more frequently present in JAK2V617 positive ET. 
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Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders characterized by 
the proliferation of one or more of the myeloid lineages (erythroid, granulocytic, 
megakaryocytic, or mast cell). During the earlier phases there is proliferation and 
maturation of the neoplastic cells in the marrow, resulting in increased numbers of mature 
granulocytes, red blood cells (RBCs), and/or platelets in the peripheral blood. Splenomegaly 
and hepatomegaly are commonly seen, which are caused by the sequestration of excess 
blood cells or extramedullary hematopoiesis (EMH), or both. Each MPN entity has the 
potential to progress to bone marrow failure resulting in myelofibrosis, ineffective 
hematopoiesis and transformation to an overt blast phase (defined by ≥20% blasts in the 
blood or bone marrow), or a combination of any of these events. Over the course of the 
disease accumulating genetic defects usually accompany morphologic evidence of disease 
progression .There are eight neoplasms classified under myeloproliferative neoplasms 
according to World Health Organisation (WHO). (2) 
 
 Chronic myelogenous leukaemia (CML), BCR-ABL1 positive 
 Chronic neutrophilic leukaemia (CNL) 
 Polycythaemia vera (PV) 
 Primary myelofibrosis (PMF) 
 Essential thrombocythaemia (ET) 
 Chronic eosinophilic leukaemia, not otherwise specified (CEL, NOS) 
 Mast cell disease (MCD) 
 Myeloproliferative neoplasm, unclassifiable (MPN, U) 
The present study will look into the various histopathological features of PMF (prefibrotic 
phase and overt fibrotic phase) and ET in detail on the bone marrow biopsies along with 
WHO CLASSIFICATION OF MYELOPROLIFERATIVE NEOPLASMS  
2 
 
relevant laboratory and clinical findings. Bone marrow biopsy is an essential part in the 
diagnostic workup of PMF and ET. Both these myeloproliferative neoplasms have definitive 
changes in the erythroid , myeloid and especially megakaryocytic lineages. Pre-fibrotic 
phase of PMF and ET often present with thrombocytosis and hence need to differentiated 
as both these entities have different modalities of treatment. The histopathological features 
of these two myeloproliferative neoplasms will be dealt in detail and comparison of findings 
will be done in the present study. 
 
 
Figure 1 Working classification of chronic myeloproliferative disorder 
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AIMS
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1) To describe the bone marrow morphology in primary myelofibrosis and essential 
thrombocythaemia. 
2) To develop a scoring system for the diagnosis of these conditions based the various histological 
parameters seen in bone marrow trephine biopsies in these groups of patients. 
3) To determine whether such a scoring system reliably distinguishes between ET and prefibrotic 
phase of PMF. 
4) To compare the blood and bone marrow findings in patients with and without JAK2V617 
mutations. 
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Historical Perspective: 
Surgical trephine biopsy is an older procedure than needle aspiration of the marrow. 
Pianese in 1903 was the first to obtain marrow from the epiphysis of the femur. 
Sternum, iliac crest and tibia were subsequently used by workers for trephine biopsy. 
Thus bone marrow aspiration continued to remain an important diagnostic tool for the 
diagnosis of  haematological  disorders. But in cases of fibrosis of marrow aspirates usually 
results in dry tap and hence trephine biopsy is vital is arriving at a correct diagnosis .(1) 
Jamshidi and Swaim in 1971 devised a new biopsy needle which is now used for bone 
marrow trephine biopsies. 
BONE MARROW STRUCTURE 
Bone marrow is a  soft, semisolid, red gelatinous substance which occupies the medullary 
cavities of the axial skeleton and in  adults, bone marrow is the 5 primary site of  
haematopoiesis and is composed of bone, blood vessels , lymphatics and haematopoietic 
tissue.(1,2) The medullary cavity is encased by trabecular bone consisting of periosteum, 
cortical and the subcortical  bone. The medullary cavity contains hematopoietic cells, 
stromal cells and extra-cellular matrix. Arterioles, sinusoids and peripheral nerves traverse 
the interstitial space. (1) 
The age of the patient is taken into consideration while assessing bone marrow cellularity 
which refers to relative amount of haematopoietic and fat cells with .The cellularity is 
highest in the first decade and gradually decreasing  to around 29% by 8th decade (1). 
NORMAL MARROW STRUCTURE: 
ERYTHROID CELLS: Erythroid series of cells are in inter-trabecular location forming 
islands, nodules or clumps. The immature cells are in the centre of the island, with 
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mature cells at the  periphery of the islands. Reticuloendothelial cells are seen in the vicinity 
of the erythroid islands. All the stages of maturation can be seen in the population. Normal 
myeloid-erythroid ratio in  a  trephine  biopsy is 1.5-3:1. 
GRANULOCYTES: All the series of granulocytes and their precursors are identifiable 
in the bone marrow biopsy. They are located near the bone trabeculae (paratrabecular).The 
more mature cells are towards the marrow space with immature forms near the  bone 
trabeculae. Neutrophils and eosinophilis are readily identified (larger and yellowish red 
granules). Basophils are infrequently seen. (1,3) 
MEGAKARYOCYTES: They are perisinusoidal in location with platelets directly shed into the 
sinusoids. These are the largest cells seen in the bone marrow ranging in size  from 12-150 
microns . Mature megakaryocytes show eosinophilic cytoplasm with variable granularity, 
the nucleus being  coarsely cerebriform and multilobated. Emperipoliesis may be seen in the 
megakaryocytes. (1) 
MONONUCLEAR MACROPHAGE SYSTEM: 
MONOCYTE SERIES: Monoblasts are morphologically similar to myeloblasts except 
that their nuclear shape may be slightly clefted or lobulated. Monocytes (15-18 microns) 
have abundant cytoplasm with intracytoplasmic vacuoles with eccentrically placed kidney  
shaped nucleus with fine and lacy chromatin. Macrophages are derivatives of monocytes 
and function as phagocytic cells in the bone marrow and other tissue sites. Macrophages are 
larger than monocytes measuring  20-30 microns in diameter with nucleus being  large, 
round to oval with lace-like chromatin and  have abundant pale blue vacuolated cytoplasm 
which contain azurophilic granules . They are present usually  in the centre of the erythroid 
islands , plasma cell islands, and adjacent to the reticuloendothelial cells. 
LYMPHOCYTES: The earliest morphologically identifiable cells are lymphoblasts 
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which are usually present in the intertrabecular region. They have a high N/C ratio with a 
narrow rim of deep blue cytoplasm and an oval hyperchromatic nucleus with one 
or two nucleoli ,measuring  7-10 microns in diameter and  characterized by a round nucleus 
with coarse, condensed chromatin, inconspicuous nucleoli and scanty blue cytoplasm. 
PLASMA CELLS: The characteristic location of plasma cells is along the adventitia of 
small blood vessels but they can be found singly and in groups with intertrabecular location  
and measuring  10-18 microns and with an eccentrically placed  nucleus , coarse chromatin 
and deeply basophilic cytoplasm containing a perinuclear clear zone. 
MARROW STROMA: 
Bone marrow stromal cells consist of adipocytes, osteoclasts osteoblasts, endothelial cells 
and fibroblast-like reticular cells. Adipocytes (fat cells) are the largest cells in the bone 
marrow stroma. They lie in close contact with haematopoietic cells and other stromal cells. 
Osteoblasts are large, ovoid or cuboidal cells measuring 20-50 microns in diameter having a 
small eccentric nucleus and an abundant basophilic cytoplasm with a clear Golgi zone 
located away from nucleus. 
Osteoclasts are large, multinucleated cells with abundant cytoplasm which contains 
numerous azurophilic granules measuring about 100 microns or greater in diameter. The 
individual nuclei are separate, uniform and round. Endothelial cells are elongated cells 
containing a flat nucleus with condensed chromatin and a moderate amount of cytoplasm. 
Reticular cells are group of cells that form a reticulum or syncytium. These cells are 
associated with reticular fibers which they produce and which form a three dimensional 
supporting network that holds the vascular sinuses and haematopoietic elements. The fibers 
can be visualized by light microscopy and after silver staining.For proper assessment of 
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marrow cellularity, a trephine biopsy specimen needs to be at least 1.6cm long before 
processing and contain five to six intertrabaecular spaces. 
Bone marrow trephine biopsies are used in diagnosis of a variety of haematological 
disorders such as leukaemias, staging marrows for lymphomas and other solid tumours. 
There use is utmost vital importance in cases of marked fibrosis as shown in table 1 and 
table 2. 
 
Table I. Conditions   with increased fibrosis (reticulin fibrosis), but not associated with 
collagen fibrosis.(1,4) 
Conditions 
 Hairy cell leukaemia 
 HIV infection 
 Visceral leishmaniasis 
 Pulmonary arterial hypertension 
 Treatment with hematopoietic growth factors. 
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Table 2. Causes of  bone marrow fibrosis, GRADE 4 (diffuse, often associated  with coarse 
reticulin fibre network with areas of collagenisation ) (1,4) 
 
 Primary myelofibrosis(PMF) and secondary myelofibrosis associated with  essential 
thrombocythaemia (ET) and Polycythaemia rubra vera(PRV) 
 Malignant disease such as Acute megakaryoblastic leukaemia , chronic myeloid 
leukaemia(CML),  leukaemia such as (Acute myeloid leukaemia (AML), Acute 
lymphoblastic leukaemia(ALL)), systemic mastocytosis , lymphomas (Hodgkin and  
Non-Hodgkin lymphoma Adult T-cell leukaemia/lymphoma and Myelodysplastic 
syndromes (particularly secondary MDS), Multiple myeloma and tumours  
metastasising  to the bone. 
 Paroxysmal nocturnal haemoglobinuria (PNH) 
 Bone and connective tissue diseases such as Osteopetrosis, Hyperparathyroidism 
(Primary and secondary ) , Rickets  associated with vitamin D deficiency and renal 
rickets, Osteomalacia and  Primary hypertrophic osteoarthropathy. 
 Chronic infections such as Tuberculosis , other granulomatous diseases such as 
Histoplasmosis  and  Osteomyelitis (Focal or localized ) 
 Grey platelet syndrome 
 Autoimmune conditions such as  Systemic lupus erythematoses (SLE), Systemic 
sclerosis ,Sjogren syndrome and  Autoimmune myelofibrosis 
 Antiphospholipid antibodies 
 Paget’s disease of the bone 
 Miscellaneous conditions such as bone marrow necrosis, radiation to the bone 
marrow , sites of healing fracture and sites of  previous trephine biopsies 
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Primary Myelofibrosis (PMF) is a non specific response to various injuries and diseases that 
involve the bone marrow. It is mediated by a numerous cytokines released from 
 megakaryocytes 
 cells of the monocyte-macrophage lineage, 
 Bone marrow stromal cells. 
Marrow fibrosis can be associated with infections or inflammatory conditions that involve 
the bone marrow .It usually accompanies neoplastic diseases such as carcinoma or 
lymphoma when they have involvement of the bone marrow. Majority of the myelofibrosis 
cases are associated with myeloproliferative neoplasms (MPN). PMF is not associated with 
other secondary conditions and stands out because of a prominent role that bone marrow 
fibrosis plays in pathogenesis of the disease process. (5,6) 
Primary myelofibrosis 
Primary myelofibrosis (PMF) is a clonal disorder of the bone marrow which forms a part of 
the spectrum of myeloproliferative neoplasms (MPN). PMF (which was earlier known as 
agnogenic myeloid metaplasia) is characterised by the proliferation of megakaryocytes and 
granulocytes, extramedullary haemopoiesis and progressive fibrosis. In the early stages of 
myelofibrosis, the marrow is hypercellular.  There is progressive splenomegaly due to extra 
medullary haemopoiesis (EMH). The liver may also be involved in EMH.  As the disease 
progresses, the marrow shows a progressive increase in the number of the reticulin fibres 
that form its structural framework. In the end stage, the marrow is largely replaced by 
markedly thickened reticulin fibres with areas of collagen fibrosis. The development of 
osteosclerosis reduces the marrow space further. (5,6) 
Two phases of the disease are recognized: 
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 The early stage of PMF is also known as the cellular or prefibrotic phase. At this stage, 
the bone marrow is hypercellular, and the reticulin fibres are normal or only slightly 
increased.  EMH is minimal and may be accompanied by thrombocytosis. 
 In the end (fibrotic) stage, the marrow is usually hypocellular due to extensive 
reticulin and collagen fibrosis. The development of osteosclerosis reduces the marrow 
space further. The peripheral blood shows a leukoerythroblastic blood picture 
(LEBP).The spleen is greatly enlarged due to EMH. Hepatomegaly may also be seen  
(6). 
The overt fibrotic phase of PMF has an estimated occurrence of 0.5-1.5 per 100000 persons 
per year. PMF commonly occurs in the sixth to seventh decade of life, but can also be seen 
in the fifth decade and both sexes are equally affected. Children are rarely affected and only 
isolated cases have been reported. Progression to  the fibrotic stage is gradual , usually 
occurring over several years, and is due to the release of cytokines from megakaryocytes, 
platelets, macrophages and lymphocytes resulting in fibrosis and vascular proliferation in 
the bone marrow.(6) 
Clinical findings 
PMF usually develops in the fifth and sixth decade, and affects males and females almost 
equally. PMF has an insidious onset. Almost a third of patients are asymptomatic and are 
diagnosed when routine testing shows anaemia or thrombocytosis. 
In the early stage before significant fibrosis sets in, patients usually present with 
constitutional symptoms such as fatigue, weight loss and fever.  Other symptoms may    
night sweats, diffuse bone pains and episodes of bleeding or thrombosis due to elevated 
platelet counts. Weight loss is defined as a loss of >10% over a period of six months (6) 
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As the disease progresses, and fibrosis sets in, symptoms may be related to anaemia which 
is also the most common cytopenia reported with PMF. (5, 6) 
Splenomegaly and hepatomegaly become increasingly prominent as the disease progresses. 
Splenomegaly may be associated with abdominal discomfort or acute abdominal pain due to 
splenic infarction which have been commonly reported in PMF. Hepatomegaly results from 
EMH in the fibrotic stage of PMF and is usually accompanied by portal hypertension, ascites 
and variceal bleeding. Portal hypertension can result from massive splenomegaly (Banti’s 
syndrome) or contribute to the development of splenomegaly. Gout and renal stones 
related to hyperurcemia may also be seen. (5,6) 
Clinical findings 
The usual onset of myelofibrosis is in the fifth and sixth decade. There is no sex predilection 
The onset of PMF is usually insidious with almost 30% of patients being asymptomatic at 
presentation, when their illness is discovered by a routine blood count that reveals anaemia 
or raised platelet counts (thrombocytosis). (5, 6) 
In the prefibrotic stage, symptoms are fatigue, easy bruisability and loss of weight which 
have commonly been reported. Splenomegaly and hepatomegaly are usually absent or only 
of mild to moderate degree. Patients in this phase may have episodes of bleeding or 
thrombosis due to elevated platelet counts. Often the clinical picture overlaps with another 
MPN such as ET. (6) 
The latter stages of PMF, i.e. after fibrosis sets in (fibrotic stage) symptoms are usually 
related to anaemia which is also the most common cytopenia reported with PMF. 
Portal hypertension is common in patients with PMF and it can result from a massive 
splenomegaly (Banti’s syndrome) or it contributes to development of splenomegaly. Gouty 
arthritis and renal stones related to hyperurcemia may be seen. (6) 
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JAK2V617F mutations may be found in around 50% of patients in fibrotic phase and predicts 
the progression to a large splenomegaly and leukemic transformation in case of primary 
myelofibrosis (PMF) .(7) JAK2V617 mutation status in prefibrotic phase of PMF has been 
reported of late in few literatures. 
Pathogenesis of PMF 
PMF is accompanied by changes in bone marrow stroma and elevated levels of circulating 
cytokines, especially in PMF. These cytokines are released from the abnormal 
megakaryocytes as well as monocytes and nonclonal stromal cells such as fibroblasts. (8) 
Elevated cytokine expression in PMF represents an inflammatory response and contributes 
to the bone marrow fibrosis and constitutional symptoms which is associated with elevated 
levels of IL-6 and IL-8.Splenomegaly is associated with HGF .Transfusion-dependent anaemia 
is associated with elevated levels of interleukins (IL-2R, IL-8, IL-10, MIP-1and MCP-1). 
Leukocytosis in PMF occurs due to IL-2R, HGF and IP-10 and thrombocytopenia with 
elevated levels of IP-10. (8) 
Cytokines that promote increased vascularity and connective tissue deposition include 
 macrophage inflammatory protein 1-β(MIP-1β) 
 tissue inhibitor of metalloproteinase, 
 insulin-like growth binding factor-2, 
 Tumor necrosis factor-α (TNF), the levels of which are also markedly increased in 
PMF. 
Plasma levels of many cytokines are elevated in myelofibrosis.(5) 
Marrow fibrosis is due to synthesis and release of Fibrogenic factors such as platelet- 
derived growth factor (PDGF) and transforming growth factor-β(TGF-β) by the neoplastic 
megakaryocytes and platelets seen in PMF. (5) (7) 
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Increased serum levels of vascular endothelial growth factor (VEGF) results in prominent 
neoangiogenesis particularly in the bone marrow and the spleen. An increase in the micro 
vascular density in the bone marrow and spleen   correlates with the  degree of fibrosis and  
EMH .(8) 
Nuclear factor- kβ (NF-kβ) also has a role in the development of BM fibrosis in PMF 
myelofibrosis. Activation of NF-kβ induces the production of IL-1 and TGF-β in monocytes. 
(9) 
β- FGF is a multifunctional growth factor which has a potent mitogenic effect on stromal 
cells. Extremely high levels of circulating β- FGF are seen in MF. β FGF is released by 
abnormal and dysplastic megakaryocytes into the surrounding stroma and stimulates 
stromal cells. In PMF, also βFGF binds to the vascular endothelial cells and contributes to 
angiogenesis in idiopathic myelofibrosis. (10) 
All these cytokines cause excessive deposition of collagen in the bone marrow, leading to 
pancytopenia and extramedullary haematopoiesis. The commonest site of extramedullary 
hematopoiesis is the spleen, followed by the liver. The splenic red pulp is expanded by the 
presence of granulocytic and megakaryocytic cells. Megakaryocytes are often the most 
conspicuous component of EMH. The debilitating symptoms seen in cases of myelofibrosis 
(PMF) are driven by the combined effects of elevated levels of proinflammatory cytokines 
and massive splenomegaly. (6) 
Genetic changes play a major role in the development of PMF. The most important is the 
being JAK2V617F mutation found in about 50% of PMF. (6) This will be discussed in a 
subsequent section. 
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Elevated levels of IL-8 and IL-2R are seen in most cases and are associated with disease 
prognostication and phenotypic correlations. Increased plasma levels of these two cytokines 
has showed significant association with 
a) constitutional  symptoms  
b) transfusion need 
c)  leukocytosis 
d) overall and leukaemia-free survival  in patients with PMF.(8) 
Complex pathobiologic genetic mutations contribute to the development of PMF. The most 
important being JAK2V617F mutation resulting in gain of function point mutation and will 
be dealt in detail in the genetics subheading. 
 
 
Figure 2- showing the potential cell cytokine interactions in primary myelofibrosis (PMF) 
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Morphologic features Definition 
Staghorn nuclei Large cells with deeply lobulated nuclei 
surrounded by mature cytoplasm 
Cloud-like nuclei Enlarged, bulbous, plump nuclei with decreased 
amount of cytoplasm 
 
Naked nuclei Compact hyperchromatic megakaryocyte nuclei 
without visible cytoplasm 
Dysmorphic nuclei Hyperchromatic nuclei with bizarre shapes 
 
 
Hyperlobulation Hyperlobulation >6 nuclear lobules; lobules 
often completely separated by cytoplasm 
Hypolobulation Hypolobulation <4 nuclear lobules surrounded 
by ample mature cytoplasm 
 
Dense clustering Dense clustering At least 4 megakaryocytes lying 
back-to-back without being separated by other 
cells 
Loose clustering Dispersed cluster of at least 3 megakaryocytes 
without close contact 
 
 
Small megakaryocyte cytoplasm Megakaryocytes <4 myeloid cells in largest 
dimension 
 
Large megakaryocyte cytoplasm Megakaryocytes >8 myeloid cells in largest 
dimension 
 
Dysmorphic megakaryocyte cytoplasm Dysmorphic megakaryocyte cytoplasm, small to 
large megakaryocytes with abnormal N/C  ratio 
and a shape other than round 
Myeloid erythroid ratio Myeloid/erythroid ratio of estimated numbers of 
myeloid and nucleated erythroid cells. 
Dilated sinusoids Dilated sinusoids Visible sinusoids that may or 
may not be filled with hematopoietic cells. 
Table3.   Definition of morphologic features (11) 
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The above table lists the commonly used terms in the reporting of myeloproliferative 
neoplasms. 
Diagnostic Criteria 
The diagnosis of PMF as defined by the WHO classification (Thiele et al, 2008), is based on a 
combination of features comprising of clinical, morphological, cytogenetic and molecular 
genetics  and requires  3 major and at least  2 minor criteria to be fulfilled. 
WHO criteria for the diagnosis of myelofibrosis 
Major criteria 
1) Presence of megakaryocyte proliferation and atypical megakaryocytes (small to large 
megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous 
cloud-like nuclei or irregularly folded nuclei and dense clustering of megakaryocytes ) which 
is usually accompanied by reticulin or collagen fibrosis. 
Or 
In the absence of significant reticulin fibrosis, megakaryocyte changes must be accompanied 
by increase in cellularity, which is characterised by granulocytic proliferation and often 
decreased erythropoiesis (i.e. prefibrotic- cellular phase disease). 
2) Not meeting the WHO criteria of 
i) Polycythaemia Vera (This requires failure of iron replacement therapy to increase 
haemoglobin level to the polycythaemia vera (PV) range in the presence of decreased serum 
ferritin. Exclusion of polycythaemia (PV) is based on haemoglobin and hematocrit levels, and 
red cell mass measurement levels are not required.) 
ii) BCR-ABL1+chronic myelogenous leukemia CML) (This Requires the absence of BCR-ABL1 
fusion) 
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iii) Myelodysplastic syndrome (This requires the absence of dyserythropoiesis and 
dysgranulopoiesis) 
iv) Other myeloid neoplasms. 
3) Demonstration of molecular markers such as JAK2V617 mutation or other clonal markers 
such as (MPLW515K/L). In the absence of clonal marker there should be no evidence that 
the bone marrow fibrosis or other changes are secondary   to 
 infection 
 autoimmune disorder 
 other chronic inflammatory conditions 
 Hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy or toxic 
chronic myelopathies.(Note: Patients with conditions associated with reactive 
myelofibrosis are not)immune to PMF, and the diagnosis should be considered in 
such cases if other criteria are met).(5,6) 
Minor criteria 
1) Leukoerythroblastic blood picture showing (nucleated red blood cells(NRBCs) along with 
immature precursors of myeloid cells (Blasts<20%,promyelocytes,myelocytes, 
metamyelocytes and band forms) and tear drop cells) (Degree of abnormality could be 
border line or marked.) 
2) Increase in serum lactate dehydrogenase level (LDH) (Degree of abnormality could be 
border line or marked.) 
3) Anaemia (Degree of abnormality could be border line or marked.) 
4) Splenomegaly (Degree of abnormality could be border line or marked.)(4,5) 
Beer et al has shown that a serum LDH of twice an upper limit of normal (normal range 120-
240mg/dl) is a reasonable discriminator between PMF from ET/PV. In contrast to other 
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minor criteria an unspecified increase in LDH levels lacks specificity as a diagnostic  criteria 
for PMF as raised LDH levels are also seen in ET/PV. (12) 
 
Laboratory findings 
Peripheral blood  smear: 
Patients diagnosed with myelofibrosis show a leukoerythroblastic blood picture along with 
pancytopenia. The blood film is leukoerythroblastic i.e. both nucleated RBCs and 
erythroblasts are present along with immature WBC (blasts<20%, promyelocytes, 
metamyelocytes, myelocytes and band forms) and RBCs shows anisocytosis and 
poikilocytosis resulting in Teardrop RBCs. The RBCs also show polychromasia. Granulocytes 
and platelets may show features of dysplasia. In the early stages of the PMF the peripheral 
blood film may show thrombocytosis and leukocytosis. In the later stages of PMF there is 
reduction in counts of all three cell lines resulting in pancytopenia, leukoerythroblastic 
blood picture and tear drop poikilocytes become evident. Often there are some giant 
platelets and occasional circulating micro megakaryocytes. (13, 14) 
 
 
Bone marrow aspirate: In the Prefibrotic phase of PMF, the aspirate would be hypercellular 
with increase in all cells (erythroid, myeloid and megakaryocyte) of all lineages. There may 
Figure  3:  showing a  
leukoerythroblastic blood picture 
in a case of myelofibrosis 
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be left shift in myeloid lineage. The maturation of these cells is normal, but there may be 
some dysplastic megakaryocytes showing hyperchromatic nuclei with clumped chromatin 
and increased N/C ratio. In the later stages of PMF there is no aspirate obtained resulting in 
a dry tap, due to increased   deposition of reticulin. (5, 6) 
Bone marrow trephine biopsy: The examination of bone marrow trephine biopsy is critical 
for diagnosis of myelofibrosis. 
Prefibrotic phase: In the prefibrotic phase of myelofibrosis the bone marrow biopsy(BTB) is 
hyper cellular with  increase in number of neutrophils and megakaryocytes .The myeloid 
cells show a mild shift to left, band forms, myelocytes , metamyelocytes  are seen and the 
recognition of a significant degree of granulocytic proliferation is important to distinguish 
prefibrotic phase of PMF from ET.(14) In most cases the erythropoiesis is reduced in 
quantity, but immature erythroid precursors are prominent.The megakaryocyte morphology 
is markedly abnormal which is essential to the recognition of the prefibrotic phase of 
myelofibrosis(PMF).There is clustering of megakaryocytes including small (>3 
megakaryocytes) and large (>7 megakaryocytes) clusters along with dense (at least 4 
megakaryocytes lying back-to-back without being separated by other cells) and loose 
clusters (dispersed clusters of at least 3 megakaryocytes without close contact).(11) Loose 
clusters  can be seen in ET and PV but dense clusters are more specific for  PMF, indicating 
its importance in the  diagnoses of  PMF.(5,11)  There is variation in size of the 
megakaryocytes such as  small megakaryocytes are also seen. These megakaryocytes are 
frequently adjacent to the bone marrow vascular sinuses (Paratrabecular location) and bone 
trabaeculae. The notable abnormalities of megakaryopoiesis include anisocytosis, abnormal 
nuclear- cytoplasmic ratios, abnormal chromatin clumping ,dysmorphic nuclei 
(hyperchromatic nuclei with bizarre shapes) and enlarged, bulbous, plump nuclei with 
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decreased amount of cytoplasm (cloud like nuclei and hyperlobate (>6 nuclear lobules; 
lobules often completely separated by cytoplasm) (11). Gianelli et al showed that the 
recognition of dysmorphic megakaryocytes is important, demonstrating that besides dense 
clustering, dysmorphic features of the megakaryocytes discriminate prefibrotic phase of 
PMF from ET.(15) Dysmorphic megakaryocytes were seen more often seen only in 
prefibrotic phase of PMF and PMF, indicating its specific importance in PMF.(15,16) The 
megakaryocyte histology is specific for PMF and not for any other myeloproliferative 
neoplasm. Bone marrow morphological examination is crucial in distinguishing the pre 
fibrotic phase of PMF from ET. (5) 
 Brousseau et al (17) evaluated of 102 ET, 18 prefibrotic phase of PMF and seven PMF over a 
period of 15 years. They devised a scoring system to differentiate between ET and the 
prefibrotic phase of PMF on the basis of 9 parameters, attaining a global maximum score of 
10. They stated that a score of (<=3) would clearly favour a diagnosis of ET (<=3) while a 
score of ( >=6) would clearly favour prefibrotic phase-early PMF. They also suggested that 
scores of 4–5 were not unequivocally in favour of either condition. 
 Brosseau et al found that 21 /120 cases had scores of 4-5; thus, they did not assign these 
“grey zone” cases to either category 
Fibrotic phase: The cellularity of bone marrow is markedly reduced with occasional foci of 
hypercellularity seen in the trephine biopsy. There will be normocellular areas along with 
hypocellular areas with patches of active hematopoiesis. The hypocellular regions are 
composed of loose connective tissue and fat. Erythroid cells are markedly reduced .Myeloids 
may also be reduced with myeloblasts accounting for <10% of the bone marrow cells. 
Atypical megakaryocytes as described in the prefibrotic phase are the most conspicuous 
finding .The bone marrow shows clear cut reticulin or collagen fibrosis (MF grade 2 or 3). 
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Sometimes the bone marrow is completely devoid of haemopoietic cells, showing mainly 
small islands of haemopoietic precursors situated mostly within vascular sinuses. There is 
also significant proliferation of vessels showing marked tortuosity and luminal distention 
(sinusoidal ectasia) often associated with conspicuous intrasinusoidal hematopoiesis with 
intrasinusoidal megakaryocytes seen. The alteration in the marrow stroma in PMF is 
responsible for the presence of distended marrow sinusoids with intravascular 
hematopoiesis.(18) In the end stage of PMF, osteosclerosis will be seen with  broad, 
irregular trabaeculae that can occupies >50%of the bone marrow space. Most of the 
patients are diagnosed in the fibrotic phase of the disease. (5, 6 ) 
An accelerated phase of the disease shows 10-19% blasts in the peripheral blood and 
increased number of CD34+ cells by immunohistochemistry with cluster formation and /or a 
normal endosteal location in the bone marrow .(6) 
In cases with > 20% blasts in the peripheral blood or bone marrow at presentation only 
other findings may suggest myelofibrosis. 
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Figure -4 showing the gradual step wise progression from Prefibrotic phase of 
Myelofibrosis to Fibrotic phase with clinical and laboratory findings. 
 
Blast Phase of Myelofibrosis (BP-Myelofibrosis) 
The blast phase (BP) of myelofibrosis (either PMF, post-polycythaemia vera MF or post-ET 
MF) is synonymous with acute myeloid leukemia (AML). According to the consensus criteria 
by the International Working Group for Myelofibrosis, BP-MF is defined by either   
1) Meeting typical WHO 2008 criteria for AML in the setting of a known prior diagnosis 
of myelofibrosis (19) 
                                                            or 
       2) A persistent increase in peripheral blood blasts to a level greater than 20% for 
           8 weeks. (20) 
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The commonest leukaemia arising in a setting of myelofibrosis is AML(M7) acute 
megakaryocytic leukaemia .(21) 
The latter criteria, based on circulating blasts enables a diagnosis to be made in those 
individuals in whom an aspirate would  not possible .The number of blasts in the marrow 
cannot be determined due to  increased replacement of marrow by  fibrosis, making an 
correct estimation of blast percentage very difficult. Several genetic mutations such as 
IDH1/IDH2, IKZF deletion, NRAS/KRAS, NF1 deletion, TP53 and RUNX1 mutations have been 
associated with blast phase of myelofibrosis.(22) 
A peripheral blood blast percentage >=3% and/or a platelet count <100 x10³/µL at the time 
of diagnosis are strong and independent predictors of leukemic transformation in patients 
with primary myelofibrosis.(23) 
The majority of individuals with BP-MF usually will survive less than 1 year, despite 
aggressive treatment. (6) 
Semiquantative Grading of bone marrow fibrosis (WHO 2008 criteria) 
MF0: Scattered linear reticulin with no intersections (cross- over’s), corresponding to normal 
bone marrow. 
MF1:  Loose network of reticulin with many intersections, especially in perivascular areas. 
MF2: Diffuse and dense increase in reticulin with extensive intersections, occasionally with 
focal bundles of collagen and or focal osteosclerosis. 
MF3: Diffuse and dense increase in reticulin with extensive intersections and coarse               
bundles of collagen often associated with osteosclerosis. (5,24) 
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Genetic Studies 
Cytogenetics 
Chromosomal abnormalities occur in 32% to 48% of patients with PMF at diagnosis. The 
karyotype is used to determine prognosis. The commonly seen abnormalities are listed 
below. 
Numerical abnormalities 
 Monosomy  5,7 and 17 
 Trisomy 8 and 9 
Structural abnormalities; 
 Deletions of the long (q) arms of chromosomes 5,7,13 and 20.(25) 
 Abnormalities of 3q especially the inversion (inv) 9. 
 The iso chromosome of 17q and other abnormalities of chromosome 17. 
Deletions of 13q and 20q are prominent features of idiopathic myelofibrosis suggesting that 
gene loss and/or activation is relevant in disease pathogenesis and progression.(25-27) 
Karotype and prognosis 
Constantine S.T and his colleagues analysed karyotypic abnormalities   and its impact seen 
at the time of diagnosis on survival and stratified patients into the following three 
categories of cytogenetic abnormalities depending on the median survival of individual. The 
cytogenetic abnormality testing was done at the time of diagnosis and beyond initial 
diagnosis. 
1) Favourable abnormalities: The patients in this group had a median survival of   minimum  
of  53 months . 
                                                                
  25 
2) Unfavourable abnormalities: The median survival for this group of patients was 15 
months and 9 months for those evaluated at diagnosis and for those evaluated beyond 
diagnosis. 
3) Very unfavourable abnormalities: The survival of this group of individuals is dismal with 
all individual dying within 12 months of diagnosis. Regardless of whether the chromosome 
17 aberration was discovered at diagnosis or beyond, survival was dismal with all patients 
projected to have died by 12 months. (28-29) 
Table 4 –  Cytogenetic abnormalities and  its prognostic significance 
 Numerical abnormalities 
 
Structural abnormalities 
 
Favourable abnormalities Trisomy 9,+8  
Unfavourable 
abnormalities 
Deletions in long(q) arm in chromosome 
13,20. 
Abnormal Chromosome 5or 7 
Very unfavourable 
abnormalities 
Monosomy 17, add(17)q25 iso chromosome 17q 
Others Sole trisomy 8, Translocation inv12Q Deletions in long(q) arm in chromosome 13,or 20 + 
one other abnormality. 
 
 
A complex karyotype refers to the presence of more than two abnormalities.(25) 
Molecular findings 
Screening for somatic Janus Kinase 2 (JAK2V617F) mutation should be carried out routinely 
in patients with PMF as it is a major diagnostic criterion in the WHO classification .The JAK2 
V617F mutation is present in 45-68% of cases of PMF.  JAKV617F mutation was detected in 
68% of all patients with MPN in an Indian study. In this study, 52% of PMF were positive for 
the mutation. The presence of JAK2V617F mutation was associated with higher 
haemoglobin, higher age and higher white blood cell count. (30-40) .The JAK2V617F 
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mutation correlates with loss of heterozygosity at chromosome 9p. Jak2 plays a major role 
in haemopoiesis, especially erythropoiesis.  JAK2 transmits signals from several cytokine 
receptors such as EPO, TPO, G-CSF, GM-CSF and IL-3. 
When ligands bind to these receptors, the JAK-STAT, MAP-kinase and PI3K pathways are 
activated.    The mutation is seen in the pseudokinase domain (JH2), in exon 14 at position 
617 of the JAK2 gene. 
Mutations of this region cause constitutive activation of the kinases. This activates the 
STATs (signal transducers and activators of transcription) even without the action of 
cytokines such as EPO or TPO. Thus, the JAK2 mutation is a gain of function mutation. STATs 
act as transcription factors (TFs) regulating the expression of genes that play an important 
role in cell differentiation, proliferation, and survival. JAK2V617F mutation is commonly 
found in MPNS in approximately 96%, 50%, and 50% of patients with PV, ET, and MF. 
JAK2 has been shown to influence chromatin structure.(41,42) In hematopoietic cells, 
nuclear JAK2 phosphorylates histone H3Y41, thereby blocking the recruitment of the 
repressor heterochromatin protein 1α and allowing increased expression of several other 
genes, such as  LMO2 oncogene(43) The discovery of JAK2V617F mutation played an 
important role in the understanding the pathogenesis of BCR-ABL–negative MPN.  A 
low JAK2V617F allele positivity or burden at diagnosis acts as a strong surrogate marker and 
is associated with shortened survival in cases of PMF.  JAK2 genotyping is mandatory in the 
diagnostic workup of suspected cases of PMF according to WHO classification as it is a major 
criteria. A quantitative assay rather than a qualitative assay would be more appropriate to 
evaluate the JAK2 burden. (44) 
Testing for other mutations should be done if atypical features are present on the trephine 
biopsy, or in cases in the patients lacks a mutation in JAK2 genes. 
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Other Mutations 
1) PDGFRA and PDGFRB rearrangements should be excluded in the presence of significant 
eosinophilia, as PDGFRA/B-rearranged MPNs are highly sensitive to imatinib therapy. 
2) MPLW515L (exon 10) mutations were first described in four cases of JAK2V617F 
mutation-negative PMF (45), an occurrence that was confirmed by other studies (46-47). 
MPL mutation-positive patients were older, with a female preponderance and presented 
with a more severe anaemia (48). Several gain-of-function mutations of MPL have been 
found in exon 10, resulting in the substitution of a tryptophan 515 to a leucine, lysine, 
asparagine, or alanine. (49-53).These 5 amino acids play a major role in the cytosolic 
conformation of MPL and prevent spontaneous activation of the receptor.. 
3) Mutations in TET oncogene family member 2 (TET2) occur in approximately 15% of cases 
of PMF and are associated with older age and anaemia. There is no correlation with overall 
survival or risk of a leukemic transformation. However TET2 testing is not recommended 
routinely. TET2 (TET oncogene family member 2) is a tumour suppressor gene which is 
located in the minimal loss-of-heterozygosity (LOH) region of chromosome 4q24. The 
presence of mutant TET2 does not appear to significantly influence leukocyte count or 
platelet count in patients with PMF. (54) 
4) The clinical significance of mutations in other genes, including – IDH1/2, ASXL1, LNK, 
IKZF1, CBL and N-RAS is unclear. EZH2 mutations are seen in about 5% of cases and carry a 
poor prognosis (55).Routine screening of this large gene is still not recommended. 
5) Suppressor of cytokine signalling (SOCS) proteins are also important negative regulator. It 
inhibits JAK signalling which acts by a classic feedback loop. SOCS1-inactivating mutations 
have been described in B-cell lymphoma. Some mutations in the different SOCS have been 
found in MPNs, but they are rare in occurrence. SOCS2 may inhibit JAK2V617F signalling, 
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and its promoter is hypermethylated.  At present the role of SOCS proteins in the 
pathogenesis of MPN remains unclear. (17) 
Paediatric myelofibrosis 
Primary myelofibrosis in children is rare, with the largest series reporting the findings in 19 
children affected with PMF.(56) Children with primary myelofibrosis (PMF) often present 
with more severe manifestations and  have different histopathologic and genetic features  
from adults. They have an overall megakaryocyte hyperplasia and atypia, proliferation of 
granulocytes and decrease in erythroid precursors. Micromegakaryocytes were present, but 
there was absence of hypolobate cloud like megakaryocyte nuclei. Collagen fibrosis was also 
seen only to a mild degree, when compared with adult cases with no osteosclerosis. 
Megakaryocytic dysplasia was seen and more than 50% of patients showed eosinophilia. 
None of the children mutations show JAK2V617F mutations in contrast to adult PMF. Hence 
it is possible that different mutations than those recognised in adult cases occur in children 
or it could be that this disorder is not clonal. 
There are no reports of malignant transformation in children by either morphology or 
immunohistochemistry (IHC) for CD34. Only two mutations have been detected, namely 
changes in the number of copies of RUNX1 and monosomy of chromosome 12p similar to 
patients with leukaemia, and hence these were considered premalignant changes (57). 
Prognosis 
A number of scoring systems have been developed for PMF for prognostication and therapy 
selection, especially to determine the need for allogeneic stem cell transplantation (allo-
SCT). 
Three main prognostic score systems are in place. (33) One is the Lille score, which includes 
anaemia and leukopenia or leukocytosis (leukocytes < 4 × 10³/µL or > 30 × 10³/µL, 
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respectively) as covariates to identify 3 distinct prognostic groups. The second one, 
developed at the Mayo Clinic, introduced thrombocytopenia (< 100 × 10³/µL) and 
monocytosis (> 10³/µL).The third one is The IPSS scoring system developed by the 
International Working Group for myelofibrosis research and treatment. 
IPSS — The International Working Group for myelofibrosis research and treatment 
comprises of  haematologists, haematopathologists, and laboratory scientists which has a 
goal of providing an international platform for scientific dialogue and collaboration in  
improving the understanding and therapy of the myeloproliferative disorders such as , 
myelofibrosis. This committee meets annually to discuss and update the various criteria’s 
useful for the diagnosis and management of myeloproliferative disorders. They have  come 
up with a (IPSS prognostic scoring system ) based on an evaluation of presenting signs and 
symptoms in 1054 consecutively-studied patients diagnosed with PMF at seven different 
centres.(58)The following five adverse prognostic features were noted on multivariate 
analysis: 
i) Presence of constitutional symptoms 
 night sweats, 
 weight loss > 10% over 6 months, 
 unexplained fever (> 37.5°C) 
 diffuse  bone pains. 
ii) Age greater than >65 years 
iii) Haemoglobin less than 10 g/dL 
iv) TWBC count >25x10³/µL 
v) Circulating blast cells ≥1 percent 
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Patients were classified into four risk groups based on the presence of these variables. Each 
variable was given a score of 1.The total score was used to classify patients into four risk 
groups 
As described below: 
a) IPSS zero score: low risk 
b) IPSS one score: intermediate risk-1 
c) IPSS two score: intermediate risk-2 
d) IPSS   >= 3 score: high risk 
These groups had non-overlapping median overall survivals of 135, 95, 48, and 27 months, 
respectively. There is also an age-adjusted IPSS for patients less than 65 years of age.(59) 
Dynamic IPSS or DIPSS — Gangat et al have modified  The IPSS by the addition of a score of 
1 for the presence of constitutional symptoms and modifying the score for haemoglobin to 
2. (60) 
The DIPSS is calculated as follows: 
i) Presence of constitutional symptoms: 1 point 
ii) Age >65 years: 1 point 
iii) Haemoglobin <10 g/ dL: 2 points 
iv)Leukocyte count >25,000/ µL: 1 point 
v) Circulating blast cells ≥1 percent: 1 point 
Subjects with 
a) DIPSS zero score: low risk, 
b) DIPSS one to two score: intermediate- 1, 
c) DIPSS three to four score: intermediate-2, 
d) DIPSS 5 to 6 points were considered High risk (60) 
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In a separate analysis done by Passamonti et al done on 525 patients showed that  DIPSS 
predicted the progression of subjects with PMF to acute myeloid leukaemia (61).The 
incidence of blast phase development was 0.3, 0.7, 2.6 and 8.6 per 100 patient-years for 
those in the low-risk, intermediate-1, intermediate-2, and high risk categories, respectively. 
Worsening of the DIPSS during follow-up also appeared to predict for a significantly higher 
risk for blast phase development. 
DIPSS  Plus — IPSS-independent prognostic factors for survival in PMF have been identified. 
These include 
a) Transfusion dependence, 
b) Unfavourable karyotype (including +8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-. 11q23 
rearrangements and complex karyotype) 
c)  Platelet count (PC) <10,000/ cu mm.(58-59) 
These three additional risk factors were added to the DIPSS score to develop DIPSS-Plus by 
Gang at et al, with scoring as follows: 
Table 5- DIPSS Plus scores 
DiPSS Low risk score 0 points 
DIPSS intermediate  risk-1 score 1 point 
DIPSS intermediate risk -2 score 2 points 
DIPSS high  risk score 3 points 
Unfavourable karyotype 1 point 
Platelet count <10,000/cumm 1 point 
Transfusion need 1 point 
 
 
When the DIPSS Plus scoring system was applied to  793 consecutive patients with PMF 
which were seen at the Mayo Clinic, those with zero points (low risk), one point 
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(intermediate risk-1) two to three points (intermediate risk-2), or four to six points (high 
risk), had median survivals of 15.4, 6.5, 2.9, and 1.3 years, respectively. When this scoring 
system was applied to 299 younger (i.e., age <60 years) patients with PMF seen at the Mayo 
Clinic, median survivals (from the time of their referral) were 20, 14.3, 5.3, and 1.7 years, 
respectively, confirming the better prognosis of younger patients with PMF .(61) 
A “very high” risk category, with a median survival of nine months and a two-year mortality 
rate of 83 percent was obtained from a study of 884 patients with PMF seen at the Mayo 
Clinic for a period of 34 years (1977 and 2011). This group had either a monsomal karyotype 
or inv (3) or i(17q) abnormalities or any two of the following 
1) circulating blasts >9 percent 
2) leukocyte count ≥40,000/ cumm, 
3) or other unfavourable karyotype (i.e. complex karyotype or any sole or two 
abnormalities including +8, -7/7q-, -5/5q-, 12p-, 11q23 rearrangement). 
The difference in survival between the “very high” and “high” risk groups was explained, in 
part, by a difference in the risk of leukemic transformation (two-year incidences of 31 and 7 
percent, respectively).(61) 
Predicting leukemic transformation — Two of the three additional risk factors (i.e., 
favourable karyotype, platelet count <1, 00, 000/ cu mm) were used to construct a 
prognostic model in order to predict leukemic transformation. Those with none of these risk 
factors or those with one or two of these risk factors had 10-year risk of leukemic 
transformation of 12 and 31 percent, respectively. (61, 62) 
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VII) Essential Thrombocythaemia 
Essential thrombocythaemia is a rare chronic myeloproliferative neoplasm (MPN) that 
involves the megakaryocytic lineage. The incidence of essential thrombocythaemia is 
estimated to be 0.6-2.5-100000 person years according to the Polycythaemia vera study 
group (PVSG group).(63) 
ET is characterized by sustained thrombocytosis >= 4,50,000/cu mm in the peripheral blood 
while the bone marrow shows increased numbers of large megakaryocytes. Bone marrow 
biopsy is important at arriving at a diagnosis of ET by excluding 
 other myeloid neoplasms associated with excessive platelet counts, such as 
myelodysplastic syndrome (MDS) associated with deletion (5q) 
 myelodysplastic syndrome /myeloproliferative neoplasm (MDS/MPN), 
 refractory anaemia with ring sideroblasts (RARS) 
 the prefibrotic phase of myelofibrosis. 
A few patients may develop BM fibrosis with associated myeloid metaplasia. 
Transformation to AML or MDS is seen in less than 5% of patients. As with PMF, the 
presence of the t (9, 22) or its fusion gene, BCR-ABL1 excludes the diagnosis of ET.  The 
JAK2V617 mutation is found in 40-50% of cases of ET and helps exclude reactive causes 
of thrombocytosis. (63) 
Affected individuals usually present with episodes of thrombosis and haemorrhage. ET is an 
indolent disorder with long symptom-free intervals, interrupted by occasional life 
threatening, arterial and venous thrombotic events and hemorrhagic episodes. 
There are various systems for the diagnosis of essential thrombocythaemia as shown in 
table 6. 
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Table-   6                 Criteria for diagnosis of essential thrombocythaemia (64) 
 
WHO  2008 criteria 
Polycythaemia vera study group 
criteria 
 
Committee for British 
standards in haematology 
 
1) Sustained platelet 
count>4,50,000/cumm 
1) Sustained platelet 
count>6,00,000/cumm 
 
 
1) Sustained platelet 
count>=4,50,000/cumm 
 
 
 
 
2)Bone marrow biopsy 
showing 
megakaryocyte lineage 
proliferation (without) 
increase in neutrophil 
granulopoiesis or 
erythropoiesis 
 
 
2) Hematocrit < 40% (or normal red 
blood cell mass) 
 
 
2) Presence of an acquired 
pathogenetic mutation 
(JAK2 OR MPL) 
 
 
3)Lack of criteria 
fulfilment for 
PV,CML,PMF,MDS or 
other myeloid 
neoplasms 
3) No myelodysplastic syndrome of 
Philadelphia chromosome 
 
 
3) No other myeloid 
malignancy, 
(especially CML,MDS,PV,OR 
PMF) 
 
 
4)Presence of  
JAK2V617 or another 
clonal marker, in the 
absence there is lack of 
evidence of reactive 
thrombocytosis 
 
4)  No collagen fibrosis or(less than 
1/3 rd of biopsy area)without 
Leukoerythroblastic blood picture  
or concomitant splenomegaly 
4)No reactive cause of 
thrombocytosis and normal 
iron stores 
 
 5)No evidence of reactive 
thrombocytosis or iron deficiency 
5) Bone marrow biopsy 
showing 
increased numbers of 
megakaryocytes with 
a spectrum of morphology 
(mostly large with 
hyperlobate nuclei) and 
generally no increase in 
reticulin 
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The most common secondary (or reactive) causes of thrombocytosis are 
 infection, and  inflammation 
 iron deficiency 
 tissue damage 
 Haemolysis 
 severe exercise, 
 malignancy, 
 hyposplenism and other causes of an acute phase response. 
The platelets are mostly normal sized with a normal mean platelet volume MPV). A 
peripheral blood film may show features which may indicate an underlying cause, such 
as acute infective or inflammatory processes. A bone marrow aspirate or trephine 
biopsy if done due to a uncertainty in diagnosis will show increased number of 
megakaryocytes (megakaryocytic hyperplasia) with normal mature megakaryocyte 
morphology and an interstitial distribution without any clustering. The reticulin content 
is not increased. In cases chronic infective or inflammatory processes there may also be 
granulocytic hyperplasia and features suggestive of the anaemia of chronic disease.(65) 
Laboratory findings 
Peripheral blood 
There is marked thrombocytosis.The platelets display anisocytosis, ranging from tiny 
platelets to atypical large, giant platelets ,bizarre shapes; pseudo pods and agranular 
platelets may be seen. The TWBC count and differential count (DC) are usually within 
normal limits. Basophilia is usually absent or minimal. The red cells are predominantly 
normocytic and normochromic unless recurrent haemorrhage has led to iron deficiency. In 
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such cases the red cells are microcytic and hyphochromic. A leukoerythroblastic blood 
picture and tear drop cells are absent in ET. (63) 
Bone marrow morphology 
Bone marrow aspirate: Smears reveal markedly increased numbers of large hyperlobulated 
staghorn type megakaryocytes dispersed in the background of large sheets of platelets. 
Perls stain reveals stainable iron in aspirated bone marrow specimens in 40-70% of cases. 
(63, 66) 
Bone marrow biopsy: Normocellular or hypercellular marrow with marked megakaryocytic 
proliferation with predominance of large and giant forms of megakaryocytes displaying 
abundant mature cytoplasm and deeply hyperlobulated nuclei (stag-horn like) nuclei. The 
megakaryocytes are usually dispersed in loose clusters. Bizarre, highly atypical 
megakaryocytes such as those observed in primary myelofibrosis are not seen. Granulocytic 
proliferation is usually not seen and erythroid precursors may be found only if patient has a 
recent episode of haemorrhage. 
Reticulin is normal or minimally increased. The presence of increased reticulin or any 
collagen fibrosis excludes ET. (17,63) 
Cytogenetic changes :  include +8, abnormalities of 9q,and del (20q).Isolated del 5q has also 
been reported in ET ,careful morphological examination is required to distinguish such cases 
from MDS associated abnormalities.(63) 
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This study was carried out in the Departments of General Pathology, Haematology and 
Transfusion Medicine and Immunohaematology, Christian Medical College, Vellore. The 
period of study was from January 2009 to February 2014. 
All patients with a bone marrow trephine biopsy diagnosis of primary myelofibrosis (PMF).  
and essential thrombocythaemia (ET) were enrolled in this study. Only diagnostic biopsies 
from patients seen at CMC were included. The bone marrow trephine biopsies were 
retrieved from archives of the Pathology department and the histological features were 
reviewed in detail.  PMF was further subdivided into the prefibrotic phase and fibrotic phase 
of PMF. 
Cases already on treatment were not included in the study. The other exclusion criteria are 
listed below. 
Exclusion criteria: 
A. Myelofibrosis 
 Other preexisting myeloproliferative disorders such as chronic myeloid leukemia 
(CML), polycythaemia Vera (PV) and essential thrombocythaemia (ET). 
 Myelodysplastic syndrome with  fibrosis or other hematopoietic neoplasms. 
 Metastatic malignancy 
 Chronic Infections, autoimmune disorders and other chronic inflammatory 
conditions. 
B. Essential thrombocythaemia 
Evidence of reactive thrombocytosis such as 
 Iron deficiency 
 Splenctomy or surgical procedure 
 infections and chronic inflammatory disorders including  connective tissue disease 
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 Lymphoid neoplasms and metastatic cancer. 
The other clinical and laboratory details including case records were obtained from the 
archives and electronic databases of the departments of Pathology , Haematology and 
Transfusion Medicine and Immunohaematology. 
Parameters  recorded 
1) Clinical features 
 Age, sex, constitutional symptoms  and episodes of thrombosis or hemorrhage  as 
appropriate 
 Presence of splenomegaly and spleen size 
2) Laboratory features 
 Haemogram- complete blood count, blood picture to specifically look  for the 
presence of leukoerythroblastosis, tear drop cells in cases of PMF, evidence of 
thrombocytosis or platelet anisocytosis in cases of ET any other relevant features. 
 Serum levels of lactate dehydrogenase (LDH). 
 JAK2V617 mutation status when available. 
 Results of cytogenetic analysis including FISH for BCR-ABL1 fusion when available. 
Histopathological assessment 
Bone marrow trephine biopsies from patients with PMF and ET were reviewed in detail by 
two independent observers with different years of experience (trainee and consultant 
haematopathologist) without being aware of JAK2 mutation status . The review of each case 
included at least three slides stained with Haematoxylin and Eosin (H&E) ,Gordon and Sweet 
Reticulin (GS reticulin) and Periodic acid Schiff (PAS). The following histopathological 
features of each case were analysed: 
 Cellularity     -  Overall and lineage-wise 
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 Megakaryocyte location 
 Megakaryocyte number and size 
 Megakaryocyte nuclei  - Hyperlobate staghorn/ Hypolobate  cloudlike/ 
hyperchromatic dysplastic nuclei/ naked nuclei 
 Megakaryocyte clusters - size and density* 
 Sinusoidal ectasia 
 Intrasinusoidal hematopoiesis 
 Reticulin grade 
 Scoring  of biopsies  using CMC scoring system for all three subgroups  and  the 
Brousseau  scoring system for ET and prefibrotic PMF only. The biopsies were 
reclassified according to the scoring system (see below). 
We devised a scoring system in which each of the above parameters was assigned a score 
from 0-2 .  Using our system, the maximum possible score was 21. (Table 7) 
Our scoring system used 16 parameters both for classification into ET, prefibrotic phase of 
PMF and PMF and also for comparison of these entities. 
The scoring system devised by Brousseau which listed nine parameters to differentiate 
between ET and prefibrotic phase of PMF was also used by us to calculate the global score 
these for two conditions . (Tables 8 & 9) Using the Brousseau scoring system the maximum 
possible  score  was 10. We compared our scores and the Brousseau scores in these two 
conditions. 
There were 27 cases of ET, 13 cases of Prefibrotic phase of PMF and 94 cases of PMF after 
reclassification according to our scoring system. We compared the histological findings of 
 PMF and Prefibrotic phase of PMF 
 ET and the Prefibrotic phase of PMF 
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 Comparison of biopsies with and without JAK2 mutation. 
Statistical analysis  was done to determine which of the parameters were significant  in 
differentiating the groups. 
 
Table 7 
Scoring system devised in CMC 
                          Score 
 
Histological 
Features 
0 1 2 
Increased overall cellularity Absent Present - 
Granulocyte precursor Normal  / decreased Hyperplasia Decreased (02) 
Myeloid shift to left Absent Present  
Erythroid cellularity Normal Increased ( 01) Decreased (02) 
    
Megakaryopoiesis Normal  (00) Increased (01) Decreased(02) 
Megakaryocyte location Perisinusoidal Paratrabaecular (01)  
Type of megakaryocytes 
Size Normal Large 
 
Small 
Hypolobate cloud like 
megakaryocyte nuclei 
Absent(00)  
Hyperlobate , giant and staghorn 
megakaryocytic nuclei 
Absent (00) Present(01)  
Hyperchromatic dysplastic 
megakaryocyte nuclei 
Absent(00) Present(01)  
Naked nuclei Absent(00) Present(01)  
    
Megakaryocyte clusters ( consists of  
more than 3 megakaryocytes) 
Absent Present 
Small  -  > 4-6 megs 
Present 
Large -  > 7 megs 
Density of megakaryocyte clusters 
 
Loose – at least 3 megs without 
close contact 
Dense – at least four megs 
opposed to each other 
 
Sinusoidal ectasia Absent(00) Present(01)  
Intra sinusoidal haematopoiesis Absent(00) Present(01)  
Reticulin grade (MF 0-3)    
 MF 0-Scattered linear reticulin; 
no intersections 
MF 2-Diffuse, dense, extensive 
intersections; focal collagen 
bundles / osteosclerosis 
 
MF 1-Loose network, many 
intersections 
MF 3- As for 2 with coarse 
bundles of collagen 
 
 
For ET and prefibrotic PMF, we compared our scoring system with that described by 
Brousseau et al (1). (Table 2) .With this system, the maximum score obtained is 10. 
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Table 8-Histological parameters evaluated by Brousseau for classification of  bone marrow trephine biopsies into PMF, 
prefibrotic phase of PMF and ET. 
Histological parameters  Score 
Overall cellularity of hematopoiesis Normal 0 
Increased 1 
Reticulin fiber score MF0 0 
MF1 1 
MF2 2 
MF3 9 
Erythroblastic cellularity Normal 0 
Increased 1 
Decreased 2 
Granulocytic cellularity Normal 0 
Increased 1 
Bare megakaryocytic nuclei Absent 0 
Present 1 
Giant and staghorn megakaryocytic 
nuclei 
Absent 0 
Present 1 
Cloudlike megakaryocytic nuclei Absent 0 
Present 1 
Hyperchromatic–dysplastic nuclei Absent 0 
Present 1 
Megakaryocytic nucleo–cytoplasmic 
ratio 
Normal 0 
Increased 1 
Type of megakaryocytic clusters Loose 0 
Tight 1 
Paratrabecular megakaryocytes Absent 0 
Present 1 
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Table 9 
Scoring system to calculate the global score described by Brousseau for differentiating 
between  ET and prefibrotic PMF(17).  
                     Score   
Histopathological 
features 
0 1 2 
Overall cellularity Normal Increased  
Granulocytic 
cellularity 
Normal Increased  
Erythroblastic 
Cellularity 
Normal Increased Decreased 
Paratrabaecular 
megakaryocytes 
Absent Present  
Megakaryocyte 
clustering 
Loose Tight  
Cloud like nuclei Absent Present  
Hyperchromatic 
dysplastic nuclei 
Absent Present  
Bare nuclei Absent Present  
Megakaryocyte 
nuclear 
cytoplasmic ratio 
Normal Increased  
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Patients were also divided into two groups based on their JAK2 mutation status. The 
laboratory findings in these two groups were compared. 
Statistical Analysis: 
Data entry was done using the epidata program. 
All statistical analysis was done using  Statistical package for social sciences(SPSS) data 
software version 13. Descriptive statistics such as frequency and percentage were used. 
A P value of < 0.05 was considered statistically significant. 
Categorical variables were analysed using   χ2 test with Yates continued correction and 
Fischer’s exact test. 
Continuous variables: Shapiro- Wilk W test was done to find out if the variables followed a 
normal distribution (score >.05). 
Continuous variables with normal distribution (score >.05): Mean value was taken as a 
significant score and a paired t-test was applied for comparison of a variable in different 
groups. 
Continuous variables which did not follow a normal distribution (score <.05):   Median value 
was taken as significant and a Mann –Whitney test was done to compare the variable in 
different groups. 
A total of 159 cases were evaluated  out of which  a total of 27 cases of ET ,107  cases of 
Primary myelofibrosis (13 cases Prefibrotic phase of PMF  and 94 cases of  fibrotic phase of 
PMF ) were included in the study .The rest of the cases were excluded based on the 
exclusion criteria.(Figure 6) 
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    Figure -5 STROVE DIAGRAM OF THE WORK UP PLAN 
All bone marrow biopsies with a morphological diagnosis of primary myelofibrosis (PMF) or 
essential thrombocythaemia (ET) identified from electronic data bases of Department of 
General Pathology. 
Slides retrieved  from archives of Department of General Pathology.  
Assessment of bone marrow histology  
 and  grading of reticulin according to WHO 
(2008) and scoring according to CMC scoring 
system. See proforma  
 Prefibrotic /fibrotic stage of PMF         ET 
Correlation with clinical and laboratory features 
1) Age 
2) Sex 
3) Spleen size 
4) Constitutional symptoms - 
 5) Peripheral blood 
 Haemoglobin (Hb),  
 Total count(TC)  
 Differential count(DC)  
 Platelet count,(PC)  
 Blood picture – Leukoerythroblastic blood picture , NRBCs, blasts if any 
 Serum LDH levels 
6) Bone marrow aspirate findings  
7) Cytogenetic findings 
8) JAK2 mutation status and FISH for bcr-abl. 
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        Figure -6 Flow chart for biopsies analysed during 
the study period 
Total number of biopsies analysed during 
the study period, n=159  
25 cases excluded based on the 
exclusion  criteria . 
1)12 cases diagnosed as MDS /MPN –U on trephine 
biopsies 
2)05 cases already on treatment 
3)04 cases of autoimmune myelofibrosis 
4)03 cases had bcr-abl positivity, hence a case of post 
CML myelofibrosis 
5)01 case showed decreased cellularity 
6)01 case of ET on treatment 
 
134 cases included in the study after reclassification, 27 
cases of ET, 107 cases of PMF (13 cases of pre 
fibrotic phase of PMF, 94 cases of fibrotic phase of 
PMF) 
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There were 134 bone marrow trephine biopsies which fulfilled the inclusion criteria for 
PMF/ET during the study period.  These biopsies comprised 107 PMF (including 13 in the pre 
fibrotic phase) and 27 ET. 
Figure 7- Distribution of cases. 
 
A) Primary myelofibrosis 
 
A .1 Clinical features 
 
A.1. i  Age and sex distribution (Figure 8) 
The majority of patients (81%) were above 40 years of age .The median age at diagnosis  
was  53 years, with 76 patients being in the 40-69 age group. There were 69 males and 25 
females (sex ratio 2.8:1). 
 
 
 
 
 
 
PMF, 94 
Prefibrotic 
phase of 
PMF, 13 
ET, 27 
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Figure 8- Age and sex distribution 
 
A.1. ii   Presenting features 
Clinical details were available for 67 patients, 64 (94%) of whom had one or more constitutional 
symptoms such as drenching night sweats, weight loss (>10% over six months) and unexplained 
fever (>37.5°C). The common symptoms were easy fatigability (83%), weight loss (52 %), fever 
(49%) and anaemia (46%). Less common symptoms were a feeling of satiety as well as pruritus in 
2.5% of patients.  Splenomegaly status at presentation was available for 66 (70%) patients in 
whom mean spleen size determined by ultrasonography was 20.6cm. 
A.2. Laboratory findings at diagnosis for PMF (Table 10) 
A.2.i Peripheral blood findings 
Haemogram in PMF 
There was wide variability in the haemogram. The haemoglobin (Hb) ranged from 4.7-17.9 
g/dl, total WBC count from 1.2x10³-55.981x10³/µl and platelet count from 2x10³-10,52x10/ 
µl. Anaemia (Hb <10g/dl) was the most common cytopenia and was seen in 40% of patients. 
Leucopenia (<4 x 103/µl) was seen in 8.5% and thrombocytopenia (platelet count (<150 x 
0 
5 
10 
15 
20 
25 
30 
Age 
groups 
0-9 10--19 20-29 30-39 40-49 50-59 60-69 70-79 
                                                            Males , n=69                Females , n=25.  
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103/µl) in 2%. Circulating blasts were present in 30% of cases with blast percentages ranging 
from 1-18 . 
Blood picture in PMF 
The peripheral blood film reports were available in 77(82%) patients and showed a 
leukoerythroblastic blood picture in 66 (86%) and tear drop cells in 70 (91%). Other findings 
included anisocytosis, poikilocytosis with ovalocytes, hypersegmented neutrophils, 
eosinophilia, basophilia, thrombocytosis and large platelet aggregates. 
Serum lactate dehydrogenase (LDH) levels in PMF 
LDH values were available in 86 (91%) of patients with a median value of value of 1119 IU/l 
(range of 329-4043). 
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Table 10 - Blood findings in PMF 
Primary myelofibrosis, n=94 
Parameters Range Mean Median 
Haemoglobin(g/dl) 
 
4.70-17.90 10.40 10.48 
WBC countx10³/µl 
 
1.2-55.98 13.18 9.9 
Platelet count x10³/µl 
 
2-1052 242 202 
Number of patients with 
Anaemia(Hb<10g/dl) 
 
38 (40%)   
Leucopenia (<3.5 x 103/µl) 
 
08 (8.5%)   
Thrombocytopenia   (<150 x 103/µl) 20 (21.27%)   
Peripheral blood films available in                   77 patients 
Leukoerythroblastic blood picture 66 patients 
Nucleated red blood cells /100 WBC 1-28 
Tear drop cells 70  patients 
 
Number of patients with circulating blasts 
 
28 (30%) 
Percentage of  circulating blasts 1-18% 
Serum LDH values available in                          86 patients (91%) 
LDH IU/L 1119 (329-4043) 
 
A.2.ii  Bone marrow trephine biopsy findings in PMF ( Table 11) 
 
Cellularity in PMF 
The majority of bone marrow trephine biopsies (67, 71%) showed increased cellularity at 
diagnosis, with normal cellularity in 27 % and decreased cellularity in 2%. Myeloid left 
shift was present in 43(46%) cases. 
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Morphology of PMF (Figure 20-32) 
The most consistent feature of PMF was increase in reticulin. MF3 reticulin grade 
was present in 91 (97%) of biopsies with MF2 reticulin grade in the remaining 3%. 
Common findings (in more than 80%) 
1) Megakaryocytes in paratrabecular location - 92 biopsies (98%) 
2) Increased number of megakaryocytes - 89 (95%) 
3)  Large megakaryocytes - 81 (86%). 
     4) Hypolobate bulbous cloud-like megakaryocytes - 85(90%), 
     5) Hyperchromatic dysplastic megakaryocytes - 88(93%). 
     6)  Loose clusters of megakaryocytes - 94% 
     7)  Sinusoidal ectasia - 86 (91%) 
8) Intrasinusoidal haematopoiesis - 82 (87%). 
Less common findings 
1) Dense clusters of megakaryocytes - 70% 
2). Small megakaryocytes and naked nuclei - 41% and 53 %. 
A .2.iii   Scoring of PMF  (Table 11 and  Figure 9) 
CMC Scoring system 
The total scores for the 94 PMF were in the range of 11-21 by our 21 point scoring 
system . The majority (57, 61%) of biopsies had scores of 13-17. Scores at the extreme ends 
(11 and 21) were seen in approximately five (5%) biopsies each. The low scores (11 and 12) 
represented end stage PMF with marked fibrosis and low cellularity.  Biopsies with high 
scores ( 18-21) showed almost all the features evaluated. 
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Figure 9 - Range of scores in PMF obtained by CMC scoring system. 
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Table 11 - Histological parameters and scores in PMF, CMC scoring system (n=94) 
Score 
 
Histological 
Features 
0 1 
 
2 
 
 N %  n %  n % 
 
Cellularity Normal 
25 27 
Increased 
 
67 
 
71 
 
Decreased, with 
fibrosis 
2 2     
Granulocyte precursor 
number 
Normal 25 27 Hyperplasia 67 71 Decreased 2 2 
Myeloid shift to left Absent 51 54 Present 43 46  
Erythroid cellularity Normal 26 28 Increased 03 03 Decreased 65 69 
Megakaryopoiesis Normal 03 03 Increased 89 95 Decreased 2 2 
Megakaryocyte morphology and distribution 
Megakaryocyte location Normal  
(perisinusoidal) 
94 100 Paratrabecular 92 98  
Size Normal 92 98 Large 81 86 Small 39 41 
Megakaryocyte nuclei 
Hypolobate cloud-like 
megakaryocyte nuclei 
Absent ³ 9 Present 85 91  
Hyperlobate , giant and 
staghorn megakaryocytic 
nuclei 
Absent 59 63 Present 35 37  
Hyperchromatic 
dysplastic 
megakaryocyte nuclei 
Absent 06 06 Present 88 94  
Naked nuclei Absent 44 47 Present 50 53  
Megakaryocyte clusters ( more than 3 megakaryocytes)*** 
Small  -  4-6 megs Absent 02 02 Present 
 
92 98   
 
 
 
 
 
Large -  > 7 megs Absent 23 25    Present 71 75 
Density Loose *– at least 3 
megs without 
close contact 
88 94 Dense** – at least 
four megs 
opposed to each 
other 
66 70  
Sinusoids 
Sinusoidal ectasia Absent 08 08 Present 86 92  
Intra sinusoidal 
haematopoiesis 
Absent 12 13 Present 82 87  
Reticulin grade 
Reticulin grade 
(MF 0-3)**** 
MF 0 0 0 MF 2 3 3  
MF 1 0 0 MF 3 91 97  
*– at least 3 megs without close contact    ** – at least four megs opposed to each other 
*** Small clusters -  4-6 megs ; Large clusters -  > 7 megs 
****MF 0- Scattered linear reticulin, no intersections; MF 1-Loose network, many intersections ; MF 2-Diffuse, dense, 
extensive intersections, focal collagen bundles / osteosclerosis ; MF 3- As for 2 with coarse bundles of collagen 
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A.2.iv   JAK2 mutation status in PMF (Table 13 , Appendix-2, Figure 49) 
The JAK2V617 mutation analysis results were available for 67 cases of which 43 (64%) were 
positive for the JAK2V617 mutation. Of these 43 cases, 26 (60%) were males. 
Comparison of JAK2V617 positive PMF and JAK2 WT PMF (Table 12) 
Although the blood counts and the number of small megakaryocytes in JAK2V617 positive 
PMF were higher than in JAK2WT PMF, only the mean haemoglobin at presentation showed 
a statistically significant difference between the two groups ( 10.7 vs 9.3 g / dl in JAK2 WT 
PMF, P value =.04). There were no other statistically significant differences in the other 
parameters and histological features did not show any stastically significant differences in  
patients with and without the mutation. Details of histopathological features of these two 
groups are given in Appendix 2. 
Table 12 - Haematologic and clinical data in JAK2V617 positive and JAK2 WT PMF 
Parameters JAK2V617POSITIVE PMF 
n = 43 
JAK2 WILD TYPE PMF 
n=24 
P-value 
Number of cases 43 24  
Age at diagnosis,(median) 53 54  
Sex    
Male 26(61%) 22(92%)  
Female 17(39%) 02(8%)  
Spleen status 
Available in 31/43 16/24  
Mean spleen size by USG* 18 cm ( range 13.7-26 cm) 19.9 cm ( range 16-28 cm ) .02 
Laboratory findings at diagnosis 
Haemoglobin (g/dl) 5.1-17.9  (mean 10.7g/dl) 4.7-16.2 (mean 9.3g/dl) .04 
Leukocyte count x 10³/µl 1.7-3.3   (median 10) 1.2 -55.98   (median 8.4) .44 
Platelet count x 10³/µl 600-1052 (median 210) 2-717 (median 184) .60 
Peripheral blood films 
Findings LEBP** in 33/39 (85%) LEBP ** in 15/15 (100%) 
Number of cases with blasts 13 (30%) 9 (37%)  
Number of blasts 1-18 1-18 
LDH IU/l 
 
544-4043 ( median 1147) 329-2862 ( median 1016) .40 
* USG-Ultrasonography**LEBP-Leukoerythroblastic blood picture 
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A.2.v  Cytogenetic findings in PMF (Appendix 9) (Figure 49-55) 
A prerequisite for the diagnosis of PMF is the absence of the t (9;22) which may be 
established either by conventional cytogenetic or fluorescence in situ hybridisation (FISH) 
analysis. FISH analysis detects BCR/ABL1 fusion which is indicative of the the t(9;22) . Details 
of cytogenetic studies were available for 71 patients, all of whom were negative for the 
translocation. Conventional analysis was performed in 56 patients, 24 (43%) of whom 
showed an abnormal karyotype.  Neither form of testing was done in 14 patients. 
Of the 94 PMF studied, cytogenetic analysis was done for 56 and FISH for 71 patients. An 
abnormal karyotype was seen in 24 PMF (42%).  Neither form of testing was done in 14 
patients. 
The recurrent MPN-associated abnormalities which were also seen in this series included 
trisomies 8 and 9, deletions of the long (q) arms of chromosomes 7, 13 and 20 and the short 
(p) arm of chromosome 12. 
The most common abnormality was the deletion 20q seen in six patients followed by the 
deletion 13q  and trisomy 8 in three. Trisomy 9 and loss of chromosome 7q was seen in two 
patients, either because of a partial deletion or an unbalanced t(1;7) which resulted in 
monosomy for 7q and trisomy for 1q. Deletion 12p was seen in one patient. 
A.2.vi IPSS SCORES IN PMF (Figure 10 ) 
The IPSS score was available for 74 (95%) cases. The majority (72% ) of our patients were in 
intermediate risk 1 and intermediate risk 2 groups.  The distribution of characteristics of the 
13 high risk cases was as follows : age >65 years (61%), constitutional symptoms and Hb 
<10g/dl (100%), WBC >25,000/µl (30%), blasts >1% (84%). 
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Figure 10 - IPSS risk groups in PMF 
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B.  Prefibrotic phase of PMF 
Thirteen of the 107 PMF were in the early (cellular) prefibrotic phase of PMF. 
B .1 Clinical features of Prefibrotic phase of PMF  (Table 14) 
B.1.i   Age and Sex distribution: Eleven of the 13(85%) cases in the prefibrotic phase of PMF 
were males. All except one were adults (median age 52 years) and eight were above 50 
years .One patient was a  five-year-old  girl. (Figure 11) 
 
Figure 11-  Age and sex distribution of prefibrotic phase of PMF 
 
B.1.ii    Presenting features 
Constitutional symptoms were reported in three patients.  Spleen size was recorded in nine 
patients with median spleen size determined by ultrasonography being 18 cm. 
B.2.i  Laboratory findings in Prefibrotic phase of PMF  (Table 13) 
As for PMF, this subgroup of patients also showed marked variation in the haemogram. The 
peripheral blood films were available in six patients with findings similar to PMF. Serum LDH 
values were available for nine (69%) patients (median 926 IU/l, range 656-1056 IU/l). 
 
0 
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Sex <10 
years 
10--19 20-29 30-39 40-49 50-59 60-69 70-79 
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Table 13 - Clinical and laboratory findings in Prefibrotic phase of PMF, n=13 
Sex distribution 
Male 11(85%) 
Female 2(15%), aged 5 and 51 
Age distribution 
Adults 12, median age  52 (range 32-69 ) 
Children One, aged  five years 
Spleen status (available in 9/13) 
Splenomegaly Range 13-20 cm ; median 18 cm 
 
Haemoglobin mean 12.5 g/dl (range 8-17) 
WBC count median 20.1 x 10³/µl (range 5.2-67.1) 
Platelet count median 540 x10³/µl, (range 129 -2021) 
Circulating blasts n=2 ,  1-2% 
Peripheral blood films (n=9) 
Abnormal 6 (67%) 
Leukoerythroblastic blood picture 3 
Tear drop cells 4 
Anisocytosis,poikilocytosis,ovalocytes 1 
Thrombocytosis, basophilia 2 
Neutrophilia, eosinophilia 1 
Normal 3(33%) 
 
Serum LDH (IU/L) n= 9; range 656-1231 ; median 926 
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B.2.ii   Bone marrow trephine biopsy findings in Prefibrotic phase of PMF (Table 14, 
Figure 33-36) 
The following findings were seen in all 13 cases: 
 Increased cellularity 
 Increase in granulocytic precursors 
 Increased  numbers of  megakaryocytes 
 Large megakaryocytes 
 Paratrabecular location of megakaryocytes. 
 Loose clusters of megakaryocytes 
 Absence of  intrasinusoidal haematopoiesis 
 Reticulin grade MF1 
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Table 14 - Histological features of bone marrow trephine biopsies in Prefibrotic phase of 
PMF 
HISTOLOGICAL 
FEATURE 
 n % 
Increased overall cellularity Present 13 100 
Granulocytes Hyperplasia 13 100 
Myeloid  left shift Absent 06 46 
Present 07 54 
Erythroid cellularity Normal 05 39 
Decreased 08 61 
   
Megakaryopoiesis increased 13 100 
Megakaryocytes 
Megakaryocyte location Paratrabecular 13 100 
 Normal perisinusoidal 13 100 
Megakaryocyte size Small Present in 5/13 38 
 Large 13 100 
 Normal 13 100 
Megakaryocyte nuclei 
Hypolobate bulbous cloud like 
nuclei 
Present 9 69 
Hyperlobate , giant and 
staghorn megakaryocytic nuclei 
Absent 04 31 
Present 09 69 
Hyperchromatic dysplastic 
nuclei 
Absent 02 15 
Present 11 85 
Naked nuclei Absent 07 54 
Present 06 46 
Type of megakaryocyte clusters Small Present 13 100 
Large Present 11 84 
Loose Present 13 100 
Dense Present 08 61 
Sinusoids 
Sinusoidal ectasia Absent 09 69 
Present 04 31 
Intra sinusoidal haematopoiesis Absent 13(100) 100 
Reticulin 
Reticulin grade MF1 13(100)  
Reticulin score 0 13(100)  
Scoring 
CMC score 12-17 (median 15)  
Brousseau score 6-10 (median 8)  
 
0ther significant findings 
 Shift to left in myeloid lineage (54%) 
 Decreased erythroid cellularity (62%) 
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 Large clusters of megakaryocytes (85%) 
 Dense clusters of megakaryocytes (62%) 
 Small megakaryocytes and small clusters of megakaryocytes (38%) each. 
 Sinusoidal ectasia (31%) 
B.2.iii  Prefibrotic phase of PMF - Scores  (Table 15 , Figures 12 and 13) 
The median score obtained by our 21 point scoring system was 15 with a range of 12-17.  
With the Brousseau system, our scores ranged from 6-10 with a median score of 7. 
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Table 15 -  Prefibrotic phase of PMF- Comparison of scoring systems 
Scoring system CMC  Brosseau 
S.n
o 
Score 
Features 
0 1 2  0 1 2 
 
 
1 Overall cellularity Normal Increase
d 
n=13, 
100% 
  Normal Increased 
n=13,100% 
 
2 Granulocytic cellularity Normal Increase
d 
n=13, 
100% 
Decreased  Normal Increased 
n=13, 
100% 
 
3 Erythroid cellularity Normal 
n=5, 39% 
Increase
d 
Decreased 
n=8, 61% 
 Normal 
n=5, 39% 
Increased Decrease
d 
n=8,61% 
4 Paratrabecular 
megakaryocytes 
Absent Present 
n=13,100
% 
  Absent Present 
n=13,100% 
 
5 Megakaryocyte cluster 
density 
Loose 
n=13,100% 
Tight 
n=8,61% 
  Loose 
n=13,100% 
Tight 
n=8,61% 
 
6 Cloud-like megakaryocyte  
nuclei 
Absent 
n=4,31% 
Present 
n=9,69% 
  Absent 
N=4,31 
Present 
N=9,69% 
 
7 Hyperchromatic dysplastic 
nuclei 
Absent 
n=2,15% 
Present 
n=11,85
% 
  Absent 
n=2,15% 
Present 
n=11,85% 
 
8 Bare nuclei Absent 
n=7,54% 
Present 
n=6,46% 
  Absent 
n=7,54% 
Present 
n=6,46% 
 
9 Megakaryocyte N/C ratio Not assessed - requires morphometry 
for accurate measurement 
 Absent 
N=2,15% 
Present 
N=11,85% 
 
10 Left shift Absent 
n=6,46% 
Present 
n=7,54% 
     
11 Megakaryopoiesis Normal Increase
d 
n=13,100
% 
Decreased     
12 Megakaryocyte Size Normal 
n=13,100% 
Large 
n=13,100
% 
Small 
n=5,38% 
    
13 Hyperlobate staghorn type 
nuclei 
Absent 
n=4, 31% 
Present 
n=9,69% 
     
14 Megakaryocyte clusters  Small 
n=13,100 
Large 
n=11,84% 
    
15 Sinusoidal ectasia Absent 
n=9,69% 
Present 
n=4,31% 
     
16 Intrasinusoidal 
haematopoiesis 
Absent 
n=13,100% 
Present      
17. Reticulin MF0,MF1-
n=13,100% 
MF2,MF
3 
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Figure 12 - CMC scoring system in prefibrotic MF 
 
Figure 13 - Brousseau scores in prefibrotic MF 
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B.2.iv   JAK2 mutation in Prefibrotic phase of PMF ( Appendix 2 and Appendix 3) 
JAK2V617 mutation status was available for six cases of which five (83%) cases were positive 
for the mutation. The laboratory and histopathological features of these five cases are 
shown in Appendix 3 and Appendix 4. 
 
B.2.v   Cytogenetic findings in Prefibrotic phase of PMF (Appendix 9) 
Cytogenetic analysis was done in four patients, two of whom had abnormal karyotypes. 
One had 47 chromosomes due to trisomy 9 and a partial deletion of the long (q) arm of 
chromosome 7 and the other showed an unusual  t (4;11)(q25-q27; p13-15). 
FISH analysis was done in seven patients, all of whom were negative for BCR/ABL1 fusion. 
B.2.vi   IPSS scores  in Prefibrotic phase of PMF  (Figure14 ) 
IPSS scores were available for seven of the 13 prefibrotic phase of PMF, five (71 %) of whom  
were intermediate risk 1. 
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Figure 14 - IPSS risk groups in PMF 
 
 
 
B.2.vii  Comparison of PMF and its Prefibrotic Phase (Tables 16 and 17, and Appendix 4) 
The statistically significant differences between PMF and its prefibrotic phase were: 
 Larger spleen size in PMF (17.6  vs  20.6 cm , P value =.02). 
 Higher blood counts in the prefibrotic phase 
 Haemoglobin (mean 12.48  vs 10.48g/dl,  P value =.015). 
 Total WBC count (median 20.1  vs  9 x10³/µl , P value=.02 ). 
 Platelet count ( median  540 vs 210 x10³/µl, P value=<.0001) 
Findings seen more commonly in the prefibrotic marrow than in PMF. 
 Increased cellularity and myeloid hyperplasia (P value= .025 each). 
 Hyperlobate staghorn-type megakaryocytes (69%   vs  37%   in PMF, P value=.028) . 
Findings seen more commonly or exclusively in PMF were 
 Sinusoidal ectasia (92%  vs  69% in the prefibrotic phase, P value=<.0001) 
 Intrasinusoidal haematopoiesis (87%   vs  nil in the prefibrotic phase, P value=<.0001) 
Prefibrotic phase of PMFF-risk 
stratification IPSS   
Low risk  
Intermediate risk -1 
Intermediate risk -2 
High risk  
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A detailed comparison is shown in Appendix 5. 
 
Table 16 – Comparison of PMF and its Prefibrotic phase – significant clinical and 
laboratory data 
MF, n=67 Myelofibrosis (PMF) , n=94 Prefibrotic phase of PMF, 
n=13 
P-value 
Number of cases 94 adults 13 (one child)  
Median age at diagnosis 52 49(excluding one child aged 
5) 
 
Spleen size in cm (mean) n=66,  13.7- 26  (20.6 cm ) n=9,  13- 20 (17.6cm ) .02 
Peripheral blood 
Haemoglobin g/dl 4.7-17.9 g  (mean 10.5) 8-17 g/dl (mean 12.5) .015 
Total WBC count x 10³/µl 1.2- 55.98  (median 9.9) 5.2-67.1 ( median 20.1) .02 
Platelet count x10³/µl 6-1052  (median 210) 129-2021 ( median 540) <.0001 
LDH IU/L 329-4043 (median 1119) 656-1231(median 921) .08 
 
 
 
 
Table 17 - Comparison of Myelofibrosis and its Prefibrotic phase – significant histological 
findings 
  PMF , n=94 Prefibrotic phase, n=13 P value 
n % n %  
Increased cellularity Present 67 71 13 100 .025 
Granulocyte Precursors Increased 43 46 13 100 .025 
Hyperlobate , giant and 
staghorn megakaryocytic nuclei 
Absent 59 63 04 31  
Present 35 37 09 69 .028 
Present 88 94 11 85 .247 
Sinusoidal ectasia Absent 8 8 9   
Present 86 92 4 69 <.0001 
Intra sinusoidal haematopoiesis Absent 12 13 13 100  
Present 82 87 0 0 <.0001 
Reticulin grade MF0 - -   
 MF1 - - 13 100  
 MF2 3 3 -   
 MF3 91 97 -   
CMC score  11-21  (Score of 21 - 5) 12-17  
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C )  Essential thrombocythaemia (ET) 
Of the 134 bone marrow trephine biopsies analysed, 27 had histological features of ET. 
C .1 Clinical features of ET 
C.1. i  Age and sex distribution of ET (Figures 15 ): 
Fifteen of the 27 ET (56%) were males (figure-14).  There were 25 adults (median age 42 
years). There was only one patient below the age of 15, an eight year old girl. There was also 
a 16 -year-old girl who presented with cortical venous and superior sagittal thrombosis, who 
was positive for the JAK2 mutation.( figure-15). 
Figure  15-  Age and  Sex distribution in ET 
 
C.1. ii 
Presenting features in ET 
Details of clinical presentation were available for 18 patients in this group. Five  patients 
presented with thrombotic events , namely,  cortical venous thrombosis (two), pulmonary 
vein thrombosis and  Budd Chiari syndrome (one each) .One had non ST elevated 
myocardial infarction). All five were tested for the JAK2V617 mutation; four of these were 
JAK2V617 positive with platelet counts in the range of  634 -1484 x10³/µl. The patient 
without the mutation had a platelet count of 594 x10³/µl. 
0 
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Sex <10 10--19 20-29 30-39 40-49 50-59 60-69 70-79 
Male  Female  
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There were five patients with splenomegaly, in four of whom spleen size was measured by 
USG (range 8 -11.9). Seven patients did not have splenomegaly at presentation. Data was 
not available for the remaining 15. 
C.2 Laboratory findings in ET (Table 18) 
All 27 patients had thrombocytosis with wide variation in platelet count at diagnosis ranging 
from 434 - 1484   x10³ /µl (median 949x10³/µl).  The mean haemoglobin was 13 g/dl and  
median  WBC  count 11.9 x10³/µl  (range  7.1 0-48.2 ). Serum LDH values were available for 
18 patients with a median value of 647.50 IU/L (range 319-1402). Peripheral smear showed 
thrombocytosis on smear in 15 patients with giant platelets in three. 
Table 18 - Laboratory and clinical features of ET 
ET n=27 
Demographics  
Males 15(56%) 
Females 12(45%) 
Age 7-65 years 
Median age of adults 42 years (range 22-65) 
Males 53  (22-65) 
Females 32 (7-50) including two <18 
Children (<18) Two , aged 7 and 16 
Spleen size 
Normal 24 
Splenomegaly 5 patients, range 8 - 11.9 cm 
History of thrombosis 5 (19%), see text for details 
Laboratory findings 
Haemoglobin (g/dl) 9.4- 15.5, mean 13 g/dl 
WBC count  (x 10³/µl) 7.1-48.2, median 11.9 
Platelet count  (x 10³/µl ) 434-1384, median 949,mean 1001 
Peripheral smear n= 15 
Abnormal  
Thrombocytosis with 15 
-Giant platelets 3 
-Eosinophilia,basophilia,neutrophilia 2 
Circulating blasts 0 
Serum LDH (n=18) 
Range (LDH IU/L) 319-1402 ( median 647) 
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C.2.ii     Bone marrow trephine biopsy findings in ET (Table 19) 
The following findings were seen in all 27 ET 
 Increased  number of megakaryocytes 
 Large megakaryocyte with hyperlobate staghorn type nuclei 
 Clustering of megakaryocytes with both small and loose clusters 
 Perisinusoidal (Normal) location of megakaryocytes 
 Absence of myeloid left shift, sinusoidal ectasia and intrasinusoidal haematopoiesis 
 Reticulin grade MF0 or MF1. 
Other common findings were 
 Normal size megakaryocytes (93%) 
 Hypolobate bulbous cloud like megakaryocyte (81%) 
 Large clusters (78%) 
The other parameters were seen in less than a third of our patients . 
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Table 19 -  Histological features of bone marrow trephine biopsies in ET, n=27 
HISTOLOGICAL 
DIAGNOSIS 
ET n=27 n % 
Overall Cellularity Normal 7 26 
Increased 20 74 
Granulocyte Precursors Increased 05 18 
Normal 22 82 
Left shift Absent 27 100 
Erythroid cellularity Normal 24 89 
Increased 03 11 
Megakaryocyte location Paratrabecular 08 30 
Normal perisinusoidal 27 100 
Megakaryopoiesis Increased 27 100 
Size of megakaryocytes Small Absent 27 100 
Normal Absent 02 7 
Present 25 93 
Large Present 27(100) 100 
Megakaryocyte nuclei  
Hypolobate cloud like 
megakaryocyte nuclei 
Absent 5 19 
Present 22 81 
Present 27 100 
Hyperchromatic dysplastic 
nuclei 
Absent 24 89 
Present 3 11 
Hyperlobate staghorn type 
megakaryocytes 
Present 27 100 
Naked nuclei Absent 23 85 
Present 4 15 
Megakaryocyte clusters     
Size Small Present 27 100 
Large Present 21 78 
Type Loose Present 27 100 
Dense Absent 24 89 
Present 3 11 
Sinusoids 
Sinusoidal ectasia Absent 27 
 
100 
Intrasinusoidal hematopoiesis Absent 27 100 
Reticulin 
Reticulin MF0 5 18 
 MF1 22 82 
 MF2 and MF3 00  
Reticulin score 0 27 100 
Scoring 
Total score 5-9, median 8 8,  
Brousseau  score  , 
Median, range 
0-4, median 2 2,0-4  
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C.2.iii Scoring system  (Table 20 and Figures 16 and 17) 
The median score obtained by our 21 point scoring system was 8 with a range of 5-9.  With 
the Brousseau system, our scores ranged from 0-4  with a median score of 2. 
Table 20 –Essential Thrombocythaemia (ET) - Comparison of scoring systems 
Scoring system CMC  Brosseau 
S.no Feature / Score 0 1 2  0 1 2 
1 Overall cellularity Normal 
n=7,26% 
Increased 
n=20,74% 
  Normal 
n=7,26% 
Increased 
n=20,74% 
 
2 Granulocytic cellularity Normal 
n=22,72% 
Increased 
n=5,18% 
Decreased  Normal 
n=22, 78% 
Increased 
n=5,18% 
 
3 Erythroid cellularity Normal 
n=24,89% 
Increased 
n=3,11% 
Decreased  Normal 
n=24,89% 
Increased 
N=3,11% 
Decreased 
4 Paratrabecular 
megakaryocytes 
Absent 
n=19,70% 
Present 
n=8,30% 
  Absent 
n=19,70% 
Present 
n=8,30% 
 
5 Megakaryocyte cluster 
density 
Loose 
n=27,100% 
Tight 
n=3,11% 
  Loose 
n=27,100% 
Tight 
n=3,11% 
 
6 Cloud-like megakaryocyte  
nuclei 
Absent 
n=5,19% 
Present 
n=22,81% 
  Absent 
n=5,19% 
Present 
n=22,81% 
 
7 Hyperchromatic dysplastic 
nuclei 
Absent 
n=24,89% 
Present 
n=3,11% 
  Absent 
n=24,89% 
Present 
n=3,11% 
 
8 Bare nuclei Absent 
n=23,85% 
Present 
n=4,15% 
  Absent 
n=23,85% 
Present 
n=4,15% 
 
9 Megakaryocyte N/C ratio 
(by morphometry) 
Not assessed as accurate results are 
obtained by morphometry 
 Absent 
n=24,89% 
Present 
n=9,11% 
 
10 Left shift Absent 
n=27,100% 
Present      
11 Megakaryopoiesis Normal Increased 
n=27,100% 
Decreased     
12 Megakaryocyte Size Normal 
n=25,93% 
Large 
n=27,100% 
Small     
13 Hyperlobate staghorn type 
nuclei 
 Present 
n=27,100% 
     
14 Megakaryocyte clusters  Small 
n=27,100 
Large 
n=21,78% 
    
15 Sinusoidal ectasia Absent 
n=27,100 
Present      
16 Intrasinusoidal 
haematopoiesis 
Absent 
n=27,100 
Present      
17. Reticulin MF05(18%) 
MF1-23,(81%) 
MF2,MF3      
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Figure 16 -   CMC scoring system in  ET 
 
 
Figure 17- Brousseau scores in ET 
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C.2.iv JAK2 mutation status in ET 
JAK2V617 mutation status was available for 25(92%) of ET, with almost equal numbers of 
patients with (12, 48%) and without (13, 52%) the mutation. Five (42%) of the 12 JAK2V617 
positive cases were males and seven (58 %) were females. (Table 22 ). 
C.2.v  Comparison of  JAK2V617 positive ET vs JAK2 WT ET  ( Tables 21 , 22 and  
Appendix 6 ) 
JAK2V617 positive vs JAK2 WT  ET  - Laboratory findings 
The JAKV617 positive ET was associated with a lower median platelet count than JAK2 WT 
(777 vs 1052 x10³/ µl  , P value =.02). There were no other significant differences between 
the two groups. 
JAK2V617 positive ET vs JAK2 WT ET - Bone marrow trephine biopsy findings 
The presence of large clusters of megakaryocytes in JAK2WT (92% vs   58% , P value = .048) 
was the only statistically significant difference between the two groups. Although there 
were differences in the other parameters none were statistically significant (Appendix 7). 
Table 21 - Comparison of JAK2V617 positive and JAK2WT ET – significant differences 
Parameter JAK2V617 POSITIVE, n-12 JAK2 WILD TYPE , n=13 P value 
Platelet count x10³/µl 454 -1484  (median 777) 594-2580  (median 1052) .02 
    
Large megakaryocyte clusters 7 (58%) 12(92%) .047 
 
Cytogenetic analysis  (Appendix 9) 
Karyotypes were available for six patients and results of FISH analysis for 17. All six patients 
had normal karyotypes .Seven patients did not have either form of testing. 
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D. Comparison of  ET and Prefibrotic phase of PMF  (Table 22 ) 
The differences between ET and Prefibrotic phase of PMF were as follows : 
D.1   ET  versus Prefibrotic phase of PMF - Laboratory findings  (Table 22) 
The significant differences were 
 A higher platelet count in ET (949 vs 540 x 10³/µl, P value = .006) than in the 
Prefibrotic phase of PMF  . 
 Higher LDH levels in the Prefibrotic phase of PMF (939 vs 704 IU/L , P value = .04) 
The other differences were not statistically significant. 
 In addition, circulating blasts and a leukoerythroblastic blood picture were seen only 
in the Prefibrotic phase of PMF. 
Table 22  - ET vs Prefibrotic phase of PMF - Statistically significant laboratory findings 
 ET Prefibrotic phase of PMF P value 
Number 27 13  
Platelet count x 10
3
/
 
µl 340-2580  ( median 949 ) 129-202.1 (median 540) .006 
(LDH IU/L ) 319-1402  (median 704 ) 656-1231 ( median 939) .04 
 
D. 2   ET vs Prefibrotic Phase of  PMF  - bone marrow trephine biopsy findings  (Table 23) 
The statistically significant histological differences between ET and the Prefibrotic phase of 
PMF are listed below. 
D.2.i   ET vs Prefibrotic Phase of  PMF  -  Cellular and vascular changes 
Findings in favour of the Prefibrotic phase of PMF, not seen in any of the 27 ET : 
 Left shift in myeloid lineage (54%  vs  nil, P value=<.0001) 
 Decreased numbers of erythroid cells (62%  vs nil,  P value=<.0001) 
 Small megakaryocytes (38%  vs  nil , P value=.002) 
 Sinusoidal ectasia (31%  vs  nil, P value=.008) 
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Findings more common in the Prefibrotic phase of PMF than in ET were: 
 Paratrabecular  megakaryocytes (100  vs  30%, P value <.0001) 
 Increased cellularity (100%  vs  74%, P value = .043). 
 Myeloid hyperplasia (100%  vs  19 %, P value =<.0001). 
 Hyperchromatic dysplastic megakaryocyte nuclei  (85% vs 11%,P value =.001) 
 Naked megakaryocyte nuclei  (46%  vs 15%, P value =.032) 
 Dense clusters of megakaryocytes (62 % vs 11%,P value =.001) 
Findings which were more common in ET than in the Prefibrotic phase of PMF were: 
 Hyperlobate staghorn megakaryocyte nuclei  (100% in ET vs 69% , P value= .002) 
Table 23 – ET   vs  Prefibrotic phase of PMF - Statistically significant histological 
differences 
HISTOLOGICAL DIAGNOSIS ET n=27 PMF, n=13 P 
value 
Increased cellularity 20(74%) 13(100%) .043 
Myeloid hyperplasia 5(19%) 13(100%) <.0001 
Myeloid left shift Nil 7(54%) <.0001 
Decreased erythroid 
cellularity 
Nil 8(62%) <.0001 
Paratrabecular 
megakaryocytes 
8(30%) 13(100%) <.0001 
Small megakaryocytes Nil 5(38%) .002 
Hyperlobate, giant/ staghorn 
megakaryocytic nuclei 
27(100%) 9(69%) .002 
Hyperchromatic dysplastic 
nuclei 
03(11 %) 11(85%) <.0001 
Naked nuclei 04(15%) 6(46%) .032 
Dense megakaryocyte 
clusters 
03(11%) 8(62%) .001 
Sinusoidal ectasia Nil 4(31%) .008 
CMC score 5-9 (median 8) 12-17 (median  
15) 
 
Brosseau score 1-4 (median 2) 6-10 (median 8)  
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D.2.ii   ET vs Prefibrotic Phase of  PMF  -  Reticulin grade (Figure 18) 
All  13  Prefibrotic phase of PMF and 81% of ET  had  MF1 , therefore reticulin grade 
was not useful to distinguish between these two conditions . 
Figure 18 - ET and Prefibrotic phase of PMF - MF grade 
 
D.2.iii   ET vs Prefibrotic Phase of  PMF  - Scores  ( Table 23 and Figure 19) 
Using our scoring system, total score obtained for the Prefibrotic phase of PMF was 
12-17 vs 5-9  for ET.  The corresponding Brosseau scores were 1-4 for ET 
 Figure 19 - CMC scores in ET and Prefibrotic phase of PMF  
 
Note : JAK2V617 positive ET and JAK2V617 positive Prefibrotic phase of PMF were compared, statically significance could 
not calculated the number JAK2V617 positive prefibrotic phase of PMF were less .(Appendix 8)   
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Figure 20-Streaming of haematopoietic cells in PMF.  H&E X 200 
 
 
Figure 21-Paratrabecular megakaryocytes in PMF. H&E X 400 
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Figure 22-Hypolobate bulbous cloud-like megakaryocytes in PMF.  H&E X 400 
 
 
Figure 23-Dysplastic megakaryocyte  with hyperchromatic nucleus in PMF. H&E X 400 
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                      Figure 24-Small megakaryocyte in PMF. H&E X 400 
 
 
                             Figure 25-Naked nuclei in PMF. H&E X 400 
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                     Figure 26-Dense megakaryocyte cluster in PMF, H&E X 400 
                                     Note the absence of intervening cells 
 
 
Figure 27-Loose cluster  of megakaryocytes Prefibrotic phase of in PMF. H&E X 400 
Note The intervening cells in between the megakaryocytes .This feature is also seen in 
PMF. 
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             Figure 28-Large cluster of >7 megakaryocytes in PMF. H&E X 400 
 
Figure 29-Small cluster of 4-6 megakaryocytes in PMF. H&E X 400 
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Figure 30- Sinusoidal  ectasia with intrasinusoidal haematopoiesis in PMF. H&E X 400 
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Figure 31-Sinusoidal ectasia with intrasinusoidal  megakaryocyte in PMF. H&E X  
 
 
 
Figure 32-Osteosclerosis  in PMF. H&E X 400 
 
Figure 33-Increased  cellularity in Prefibrotic phase of PMF. H&E X 10 
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Figure 34-Hypolobate cloud-like megakaryocyte and small megakaryocyte (arrow) in  
prefibrotic phase of PMF. H&E X 400 
 
Figure 35-Hypolobate cloud-like megakaryocytes in Prefibrotic phase of PMF. 
                                                    PAS stain X 400 
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                    Figure 36-Hyperlobate stag-horn type megakaryocytes 
                                in Prefibrotic phase of PMF . H&E X 400 
 
 
 
                        Figure 37 –Clustering of megakaryocytes in ET. H&E X20 
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           Figure 38-Hyperlobate staghorn type of megakaryocyte in ET. H&E X 400 
 
Figure 39-Loose clustering of megakaryocytes in ET , PAS stain. H&E X 400 
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Figure 40-Hyperlobate staghorn type megakaryocytes 
and small cluster  of 4-6 megakaryocytes in ET, H&E X 400x 
 
 
 
Figure 41 Large cluster of >7  megakaryocytes in ET. H&E X 400 
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Figure 42 -MF0  reticulin grade in ET.GS reticulin  X 400 
 
 
Figure 43-MF1 reticulin grade in ET. GS reticulin  X 400 
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Figure 44- MF1 in Prefibrotic phase of PMF. GS reticulin X 200 
 
Figure 45- MF1 in prefibrotic phase of PMF with paratrabaecular located megakaryocytes,  
GS Reticulin x400 
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 Figure 46- MF2  reticulin grade in PMF. GS Reticulin stain X 200  
 
Figure 47- MF3 reticulin grade in PMF. GS Reticulin stain X 200 
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JAK2  V617F mutation detection by 
Allele specific PCR followed by 
agarose gel electrophoresis
1 32 54 NC 100 bp mm
Lanes: 1,2 – Jak2 Wild type
3,4 –Positive for V617F
5 – JAK2 V617F positive control
NC- Negative control
100bp MM- molecular marker
 
Figure 48 - Allele specific PCR followed by agarose gel electrophoresis 
 
 
Interphase FISH negative for BCR/ABL1 fusion 
Two red and two green signals in each cell
indicating that the t(9;22) is absent
Red = ABL1 on chromosome 9
Green = BCR on chromosome 22
 
Figure 49 –Interphase FISH  negative for BCR/ABL1 with two red and two green signals in 
each cell indicating that the t(9,22) is absent  . 
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Trisomy 8
 
Figure 50- Karyotype  in PMF  , Trisomy 8 
 
 
Deletion 13q
 
Figure 51 – Karyotype in PMF , Deletion 13q 
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Deletion 20q
 
Figure 52 – Karyotype in  PMF , Deletion 20q 
 
 
46,XY, der(1;7)(q10;p10) resulting in gain of 1q and loss of 7q
 
Figure 53 -Karyotype IN PMF,  46XY,der(1;7),(q10,p10) resulting in gain of 1q and loss of 
7q. 
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Deletion 7q and trisomy 9   
 
Figure 54 –Karyotype  in PMF ,Deletion 7q and trisomy 9  
 
Deletion 12p
 
Figure 55– Karyotype in PMF , Deletion 12p 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
  95 
 
Essential Thrombocythemia (ET),  polycythaemia vera (PV), and primary myelofibrosis (PMF) 
form part of the spectrum of myeloproliferative neoplasms (MPN). 
Primary myelofibrosis results in bone marrow failure because of replacement of marrow by 
fibrosis or transformation to acute leukaemia. The characteristic findings of a 
leukoerythroblastic picture and tear-drop cells in the peripheral smears are suggestive of 
myelofibrosis. However, these findings may not be present in every patient.  In addition, 
bone marrow aspirates in PMF seldom yield cells (dry tap). Therefore, histological analysis of 
bone marrow trephine biopsies (BTBs) is critical for the assessment of fibrosis and cellular 
composition as well as to rule out other pathology that could cause marrow fibrosis          
(secondary myelofibrosis).  In fact, BTBs are considered the gold standard to establish the 
diagnosis of PMF. 
In the initial stage of PMF, known as the prefibrotic phase, the BM is hypercellular with 
increase in abnormal megakaryocytes and minimal or no fibrosis (reticulin grade MF0-MF1). 
Thus, the histological features of the prefibrotic phase of PMF show considerable overlap 
with ET. Therefore, it is important to distinguish between the two conditions because the 
course of both diseases is very different with respect to survival  (76  vs  89% for ET) and the  
likelihood of progression to overt fibrosis or leukaemia ( 6-12%  vs  less than 1% for ET) (66) . 
As the disease progresses, there is marked fibrosis with decrease in cellular elements, 
sinusoidal dilatation and marked osteosclerosis resulting in widening of bone trabeculae 
which replace the marrow space.  This leads to peripheral pancytopenia. 
Primary myelofibrosis(PMF) 
Primary myelofibrosis has been described as a disease of the sixth to seventh decades (5,6).  
Although the median age of our patients was 53 years, over a third of our patients (39%) 
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were below 40 years of age with a male predominance. These findings are similar to a 
report by Xue et al(67) on 642 Chinese patients seen over a period of 24 years, as well as a 
study from Italy by Barosi et al, of 650 PMF over 15 years (68). There was no difference in 
the median age of our patients with and without the JAK2V617 mutation. (53vs54) 
Other clinical details were available for 67 patients, 64 (94%) of whom had one or more 
constitutional symptoms. Xue et al (67) described constitutional symptoms in 21% of 642 
PMF while Gianelli et al reported constitutional symptoms in only 5% of their 192 PMF (69). 
The most common presenting complaint was easy fatigability (83%) while about half of our 
patients, presented with weight loss or fever or were found to have anaemia.  Splenomegaly 
was present in all 66 patients in whom spleen size was recorded. Xue et al, reported 
splenomegaly in 45% of their 642 PMF (67). 
There was a wide variation in our blood counts, with values ranging from very low to very 
high. However, our mean values for haemoglobin (10.48 g/dl), total WBC count (131.8 x10³ / 
µl  )  and platelet count (242 x10³ / µl ) are similar to Xue et al(67). The mean haemoglobin 
and total WBC counts in the studies by Barosi and Kvasnicka were similar to our study, 
however, the mean platelet count was higher ( 432 and 603  x 10³/µL). (68, 70) 
Anaemia (Hb <10g/dl) was the most common cytopenia and was seen in 40% of patients. 
Circulating blasts were seen in 30 % of PMF, with >1% blasts being seen in 26% .These 
findings are similar to Xue (68). Only 86 % of our patients showed a leukoerythroblastic 
blood picture (2,5 ,6, 14). 
Serum LDH levels were considerably higher (median value of 1119 IU/L) in our patients as 
compared the reports by Kvasnicka (70) and Barosi (median 374   and 464).(60) 
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Almost all (98%) our PMF showed paratrabecular megakaryocytes as well as increased 
numbers of megakaryocytes (95%). Abnormal megakaryocytes with hyperchromatic 
dysplastic or hypolobate bulbous cloud-like nuclei, large megakaryocytes, sinusoidal ectasia,  
and intrasinusoidal haematopoiesis were consistently seen in  >  85%  of PMF. 
The majority (71%) of PMF marrows were hypercellular.  A rare (2%) but important finding, 
was markedly decreased cellularity because of extensive fibrosis and osteosclerosis. 
Less common findings were myeloid left shift (46%), naked nuclei (53%) and small 
megakaryocytes (41%).The presence of small megakaryocytes in PMF has also been 
reported by Bain and Thiele (2,71), although the WHO classification (2008) has not listed this 
finding as a characteristic feature of PMF (6). Several other studies have also documented 
the presence of naked nuclei; however, none of these studies have recorded the actual 
percentage of this feature in their biopsies. (5, 6, 72,73,74) 
Prefibrotic phase of PMF and comparison with  PMF 
 
In our study we had 13 patients with a histological diagnosis of Prefibrotic phase of PMF, 11 
of whom were males with a median age of 52 years, similar to PMF.  The spleen size showed 
a significant increase with progression of disease, from 17.6 in the Prefibrotic phase to 20.6 
cm in PMF similar to Kvasnicka et al (2 cm below the costal margin vs 4 cm in PMF). (71)  
Barosi used the spleen index (obtained by measuring the longitudinal length x transverse 
length) to determine splenomegaly. They found a spleen index of 118 cm² in the prefibrotic 
phase as compared to 181 cm² in PMF. (68) 
There were a few statistically significant differences between PMF and the Prefibrotic phase 
with regard to blood counts. Overall, as expected, the counts were higher in the Prefibrotic 
phase of PMF than in PMF, similar to that described by Thiele et al. (71)  The mean 
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haemoglobin (12.5 g/dl ) and the median platelet count ( 540  x 10³/µl) was similar to other 
studies of prefibrotic PMF ( 70,72) .The median total WBC count was higher (22 vs 12 
x10³/µl) than in  the study by Kvasnicka but similar to Buhr et al (72) . 
These findings again highlight the variability of the peripheral blood findings in these 
conditions. 
A leukoerythroblastic blood picture was seen in 33 % of the Prefibrotic phase as compared 
to 86 % of PMF in our study. Circulating blasts were seen in 15% of the Prefibrotic phase and 
30 % of PMF. Kvasnicka did not report circulating blasts in either group. (70)  Serum LDH 
levels increased as there was progression of disease from the prefibrotic phase to PMF. 
Our findings demonstrate the change in spleen size and blood parameters and development 
of a leukoerythroblastic blood picture with progression from the Prefibrotic phase of PMF to 
PMF, similar to that described by Thiele et al. (71) 
In a study of 136 cases, Barosi et al compared the features of the Prefibrotic phase and PMF. 
Patients in the Prefibrotic phase presented at a considerably lower age (mean age 38 years 
versus 54 years in PMF) with a female preponderance in the Prefibrotic phase (68).  While 
the haemoglobin and platelet counts were higher, the total WBC count was reported to be 
lower in the prefibrotic phase than in PMF. (68) They also reported decrease in serum LDH 
levels with progression of disease from to PMF. These findings of Barosi are difficult to 
explain because the prefibrotic phase is characterised by hypercellularity as fibrosis has not 
yet set in. 
These findings again highlight the variability of the peripheral blood findings in these 
conditions. 
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Bone marrow trephine biopsy findings - Prefibrotic phase vs PMF 
The Prefibrotic phase of PMF was associated with a significantly increase in cellularity and 
myeloid hyperplasia  as compared to PMF (P= <.025). Another significant difference was 
intrasinusoidal haematopoiesis with intrasinusoidal megakaryocytes which was exclusive to 
PMF and absent in the prefibrotic phase (p = <.0001), a finding which has also been 
described by several other studies. (5,6, 73, 74, 75,76) Sinusoidal ectasia was more common 
in PMF as compared to the prefibrotic phase (P = <.0001). (71) 
We also report two other megakaryocytic abnormalities which have not been described in 
the literature, one of which showed statistical significance.Megakaryocytes with 
hyperlobate staghorn-type nuclei were present in a significantly higher number of the 
Prefibrotic phase (69%  vs 37%,  P =.028).  The other hitherto unreported abnormality was 
the presence of megakaryocytes with hypolobate bulbous cloud-like nuclei (90 % of PMF vs 
100% of prefibrotic phase of PMF) 
We also noted that hyperchromatic dysplastic megakaryocytes (94% vs 85%) and naked 
nuclei (53 % vs 46%) were more common in PMF than in its prefibrotic phase. Although the 
last three differences were not statistically significant, another detailed histopathological 
study by Thiele et al has also described similar findings. (71) 
Scoring system 
As described earlier, the histological features of the prefibrotic phase of PMF show 
considerable overlap with ET, although the prognosis and treatment are very different. 
Brousseau et al (17) devised a scoring system to differentiate between these two conditions. 
Brousseau used 12 histological parameters to classify 127 cases into ET, Prefibrotic phase of 
PMF and PMF.  For comparison between the Prefibrotic phase of PMF and ET, they used 
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nine parameters to achieve a maximum score of 10.   They suggested that scores at the ends 
of the spectrum could be used to distinguish between cases of ET (score <=3)  and  
Prefibrotic phase of PMF (score >=6) ,  while interpretation might be  more difficult  with 
scores in the range of 4–5. 
We also attempted to determine whether these two conditions could be better 
differentiated histologically. Therefore, we devised our own scoring system to ensure a 
systematic and reproducible analysis of these marrows. Our scoring system which assesses 
16 histological parameters, differs in some aspects from the system of Brousseau et al.(17) 
We have included some features not scored by  Brousseau such as  left shift in myeloid 
lineage, megakaryopoiesis ,hyperlobate stag horn type nuclei and sinusoidal ectasia . We did 
not include the megakaryocyte nuclear-cytoplasmic ratio assessed by Brousseau because 
this requires morphometric analysis which may not be easily done in routine practice. Each 
parameter could be awarded a score of 0 to 2 and the maximum score that could be 
achieved was 21. 
We found that the scoring system was largely reproducible by two independent observers 
who had differing years of experience in reporting BTBs, if the definition of each parameter 
was kept in mind while scoring.  The only parameter where the observers obtained different 
scores was in the assessment of the number of large and small clusters of megakaryocytes. 
In occasional cases we had differences in MF grading. However the difference in the final 
score obtained independently by the two observers was less than 2 in all 134 cases. 
CMC Scoring in Prefibrotic phase and PMF 
Using our scoring system, we found that the range of scores in PMF and the Prefibrotic 
phase is similar in most cases. However, as expected, PMF showed a wider range of scores 
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(11-21) as compared to the prefibrotic phase (12-17). Only PMF reached scores of 18 - 21. 
Such scores accounted for about 25 % of PMF. However, the score alone cannot be used to 
categorise the phase of PMF as it is not predictive in all cases.  Despite the presence of 
reticulin fibrosis and a high MF grade, the end stage of PMF can yield scores as low as 11 
because of the low cellularity. 
Therefore, the most important difference between the prefibrotic phase and PMF was the 
reticulin grade which is MF0 or MF1 in the prefibrotic phase and MF2 and MF3 in PMF.  
Regardless of the overall score, the biopsy must be classified as PMF in the presence of 
reticulin grade MF2 and MF3. 
The scoring system showed differences between the Prefibrotic phase of PMF and ET which 
will be discussed subsequently. 
Brousseau scoring system for the Prefibrotic phase 
The Brousseau system for the Prefibrotic phase of PMF yielded scores ranging from 6-9 in 12 
cases while one had a score of 10.  Brousseau et al obtained similar scores of 6-9 in their 
study of 13 Prefibrotic phase biopsies. (17) 
Essential thrombocythaemia (ET) 
 
We had 27 cases of ET with a median age of 42 years and a male: female sex ratio of sex 
ratio of 1.25:1, similar to Tefferi et al (77).  A study of 231 ET by Chim et al reported a 
median age of 65 years.(78) 
In our study, the mean haemoglobin (12.9g /dl) and platelet count (850 -1001 x10³/µl.) were 
similar to other studies (Chinese , Tefferi et al and Cervantes et al) (77,78,79). Our mean 
total WBC count (14.54 x 10³/µl ) was higher than that reported by a Chinese study(78) and 
Cervantes et al (79) (10.4x10³ and 9.1 x10³/µl ) while Tefferi et al (77) reported a WBC count  
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of  (80.5x 10³/µl)  at diagnosis. Splenomegaly though not common was present in (11%); 
others have noted splenomegaly in 9-24%  of ET Chinese (78), Cervantes et al (79) and 
Tefferi et al (77)studies . 
The percentage of patients (19%) with thrombotic events was similar to other studies (13-
18%)  Chinese study (13%) and Tefferi (17.6%).(77,78) 
All our five ET with thrombosis were females with a mean age of 29 years and a mean 
platelet count of 911x10³/µl ; four were JAK2V617 positive (80%) .  A study by Carobbio et al 
(80) of 891 ET found that thrombotic events were more common in males and age >60 years 
with a WBC count of >11x10³/µl and JAK2V617 positivity also being risk factors for 
thrombosis. Campbell et al have also described an association between JAK2V617 positivity 
and thrombosis in 250 patients with ET. (81) 
ET is even more  rare in children.  Girodon et al studied 311 patients over a 20-year- period  
and  found  thrombosis in approximately 10-30% of children.(5)  We had two children with 
ET, one of whom presented with  cortical and superior sagittal sinus thrombosis and was 
positive for the  JAK2 V617  mutation.(82) 
Bone marrow trephine biopsy  findings 
All 27 ET biopsies showed loose clusters of megakaryocytes and large megakaryocytes with 
hyperlobate staghorn-type nuclei , both of which have also been described by several 
others(84,85,86,87,88,89,90,91,92,93). An increase in cellularity and no increase in 
granulopoiesis was seen in >70% of patients. Dense clusters of megakaryocytes which are 
typical of the Prefibrotic phase of PMF were seen in only 11 % of ET. The majority (88%) of 
cases showed MF1 reticulin grade; MF0 reticulin grade was seen in the remaining 18%. 
These findings were similar to what has been reported in other studies. (83,85,94) 
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Comparison of ET and Prefibrotic phase of PMF 
We also compared ET and the prefibrotic phase of PMF because there is considerable 
overlap between the histological features of these two conditions.  These two conditions 
have different rates of survival (10-year survival  76  vs  89%  for ET ,15 -year survival  59  vs  
80%  for ET) and leukemic transformation ( 5.8  vs  0.7 % after 10 years and 11.7  vs 2.1%  
after 15 years ) .(66,95) Moreover,  the modalities of treatment are also different. 
We found several statistically significant differences between ET and the prefibrotic phase 
of PMF. 
Peripheral blood 
Platelet counts were higher in ET (949 vs 540 x10³/µl , P value = .006 ) than in  the 
prefibrotic phase of PMF . 
Although ET cases showed lower total WBC count (11.9 vs 20.1 x10³/µl) and  LDH levels (704 
vs 939 IU/L)  than the prefibrotic phase of PMF, these differences were not statistically 
significant. 
Bone marrow trephine biopsy 
Several histological features were common to both ET as well as the prefibrotic phase of 
PMF. 
All biopsies from both ET as well as Prefibrotic phase of PMF showed increased 
megakaryopoiesis with large megakaryocytes and all the different types of megakaryocyte 
clusters; another common feature was absence of intrasinusoidal haematopoiesis which is 
seen in PMF. All the other parameters studied were present in both conditions, although 
some features were more common in one or other condition as described earlier. 
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These overlapping findings illustrate the difficulty in classifying these cases histologically as 
ET or Prefibrotic phase of PMF. The scoring system was devised by us in an attempt to refine 
the diagnostic criteria and better classify the cases with diagnostic difficulty. 
Features seen only in ET and not in the Prefibrotic phase of PMF were: normal cellularity in 
26% , normal numbers of myeloid cells in 81%  and reticulin grade  MF0 in  18%. Erythroid 
hypoplasia which was seen in 62 % of Pre fibrotic phase of PMF was not a feature of ET. 
However, when  ET was compared with the Prefibrotic phase of PMF, the only statistically 
significant histological  finding in favour of ET was the presence of hyperlobate staghorn 
megakaryocyte nuclei (Pvalue= .002) . Two studies by Thiele et al also noted that 
hyperlobate staghorn type of megakaryocyte were a common finding in ET; however, 
neither of these studies gave the percentage of biopsies with this findings. (96,97) 
There were several statistically significant findings which favoured the diagnosis of the 
prefibrotic phase of PMF, namely, granulocytic cellularity, paratrabecular megakaryocytes,  
dense clusters of megakaryocytes (P value =<.0001 each) and  naked nuclei (P value =.032). 
Gong et al also reported that these findings favoured the diagnosis of prefibrotic phase of 
PMF over ET (P value = <.05). (98)   The other significant findings we found were left shift in 
myeloid lineage and hyperchromatic dysplastic nuclei (P value =<.0001) and sinusoidal 
ectasia ( P value=.008) which were not reported by Gong  et al (98) . 
However, we must emphasise that no single feature can be used to differentiate between 
these two entities. We found that the scoring system was helpful in distinguishing between 
the two entities. 
We compared our findings in these two entities with a similar study by Brousseau et al . (17) 
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The features found to be in favour of Prefibrotic phase of PMF in both studies were 
granulocytic cellularity (P value=<.0001  vs  P value =.039*), paratrabecular megakaryocytes, 
hyperchromatic dysplastic nuclei, naked megakaryocyte nuclei  ( P value=.032 vs P value 
<.05) dense clusters of megakaryocytes (P value =<.0001  in both studies). 
Although we did not find that hypolobate cloud like megakaryocyte nuclei was a significant 
histological feature, however Brousseau(17) and Ghong et al(98) have reported that this 
favours Prefibrotic phase of PMF. Brousseau also reported increased megakaryocytic 
nucleo–cytoplasmic ratio. We did not evaluate this feature separately because this required 
morphometry for accurately measuring the N/C ratio.We included this feature as part of 
hyperchromatic dysplastic nuclei. 
Other features in favour of Prefibrotic phase of PMF found in our study but not in the 
Brousseau study were increased cellularity (P value=.043 vs .054* ) and decreased erythroid 
cellularity (Pvalue= <.0001vs.241*). Other significant features found by us but not evaluated 
by Brousseau were myeloid left shift, sinusoidal ectasia (P value=.008) and small 
megakaryocytes (P value=.002) 
In favour of Prefibrotic phase of PMF in Brousseau study only 
 Hypolobate cloud like megakaryocyte nuclei (P value =<.0001 as against P value =.09 
in our study). 
 Increased megakaryocytic nucleo-cytoplasmic ratio, (P value <.001;  not evaluated in 
our study  as accurate results can only be obtained by morphometric analysis which 
we did not do in our study. 
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With regard to ET, although we found that the presence of Hyperlobate staghorn 
megakaryocyte nuclei (P value= .002 vs .563 )(14) was statistically significant, Brousseau et 
al did not report this association. 
Thus we conclude that a scoring system better enables us to differentiate between ET and 
Prefibrotic phase of PMF.  Study of more cases would help us to identify cases that fall in the 
grey zone and validate our scoring system more robustly. 
Six  cases initially diagnosed as prefibrotic phase of PMF when the reticulin grade was 
reported as mild, moderate and severe were later reclassified as PMF when graded MF3 
according to the European consensus grading system. 
Scoring of Biopsies 
ET and PMF were compared using our scoring system as well as the Brousseau scoring 
system to determine whether the differences between these two entities could be could 
be identified consistently. 
Overall scores 
With our scoring system, we noticed a clear difference between the ET and Prefibrotic 
phase of PMF in contrast to the scores of prefibrotic phase of PMF and PMF. Using our 
scoring system, four possible cases ET were scored between12-14 and were reclassified 
as Prefibrotic phase of PMF. 
ET had scores of 5-9 while in the Prefibrotic phase of PMF, the scores were 12-17.  Nearly 
half (48%) of our ET had a score of 9.  None of our prefibrotic phase of PMF had a score of 
11. 
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Therefore, we suggest that the cut-off value of our scoring system should be 10. If such a 
score is obtained, the biopsy report should clearly state that an unequivocal categorisation 
cannot be made. 
When we used the Brousseau scoring system, our Prefibrotic phase of PMF had scores of 6-
10 while ET ranged from 0-4.  We obtained a score of 4 in 2/27 ET.  One Prefibrotic phase of 
PMF was assigned a score of 10 which was not seen in the Brousseau study.  (17). 
Based upon our findings, we tentatively suggest that the cut-off for a definitive diagnosis for 
ET be </=5 instead of </=3  as suggested by Brousseau et al.(17)  However, we will need to 
score more ET biopsies to identify cases falling  in the grey zone because  the number of 
cases studied by us ( 27 ET and 13 prefibrotic phase of PMF) are fewer than the Brousseau 
study (102 cases of ET, 18 cases of prefibrotic phase of PMF). 
IPSS Score for PMF and prefibrotic phase of PMF 
IPSS scores could be calculated for only five patients with the Prefibrotic phase of PMF, 
none of whom were in the low risk group.  In a study by Gianelli et al, the 58 MF1 prefibrotic 
phase of PMF fell into all four risk groups, with 19 % in the low risk group although the 
majority (77%)  were in the intermediate risk groups. (99) 
Our 91 PMF with MF3 reticulin grade were distributed across all four groups with 11% being 
in the low risk group. 
The 14 PMF with MF3 reticulin grade studied by Gianelli were distributed  across all four 
groups , with low risk in 07%, intermediate risk 1 in 28%, intermediate risk 2 in 43 % and 
high risk in 22 % in  14  cases of PMF.  (99) 
JAK2 V617 mutation status 
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Overall, JAK2V617 mutation analysis results were available for 73 PMF (including six in the 
prefibrotic phase) and 25 ET. 
JAK2 V617 mutation status in PMF 
Of the 73 PMF, 48 (66%) were positive for the mutation. This is similar to a study from China 
by Xu et al (67%) and is higher than what has been reported in the West (43-50 %) as well as 
another Indian study (52% of 31 patients). (67,100,101,102). Five (83%) of the six in the 
prefibrotic phase were positive for the JAKV617 mutation. Gong et al (98) found the 
mutation in 55% of 61 prefibrotic phase of PMF (5). The median age of these patients was 
56 which was similar to reports (53-61 years) .  (67, 68, 101) 
We found that weight loss was the commonest symptom; pruritus was reported by only 
2.5% of our patients unlike Tefferi et al who reported that pruritus was the most common 
symptom.  (101) 
Most of the patients had palpable splenomegaly while a Chinese study of 642 cases of PMF 
showed splenomegaly in only 45%(289). (67) 
JAK2 V617 Positive vs JAK2 WT PMF 
On comparing the  JAK2V617 positive and  JAK2WT PMF, only the mean haemoglobin at 
presentation (mean 10.7 vs 9.3 g/ dl ) showed a statistically significant difference between 
the two groups ( p value =.04) similar to Vytrva et al.(103) We did not find any other 
statistically significant differences in the clinical or histological features. 
JAK2 mutation status in ET 
The JAK2V617 mutation was present in 12 /25 (48%) ET tested. This is lower than reported 
by other Indian studies (64-70%). (35) (104)  but similar to a study by Amy et al (41% of 59 
ET )(100). Thrombotic events were seen in four of the 12 patients (33%) with the mutation. 
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These were cortical venous thrombosis (two), pulmonary venous thrombosis and Budd 
Chiari syndrome (one each). It has been reported that individuals with the JAK2V617 
mutation are prone to thrombotic events (105,106). Primignani et al and  Colazzio et al have 
reported Budd Chiari syndrome in JAK2V617 positive ET.(107,108). None of our patients had 
bleeding episodes. It is well known that ET is associated with an increased risk of 
thrombosis. However, thrombocytosis greater 800 x 103 /µL is likely to be associated with 
haemorrhage due to acquired von Willebrand disease. (108) 
JAK2 V617 Positive vs JAK2 WT ET 
We did not observe an age difference between JAK2V617 positive and JAK2 WT ET (40 vs 39) 
unlike another Indian study by Ross et al (105) which observed that JAK2V617 patients were 
a decade older (58 vs 45) (105). Campbell (106)  and Kittur et al(110) reported median ages 
of 60 and 62 years in their ET patients positive for the JAK2 mutation V617 positive ET . 
Those lacking the mutation had median ages of 52 and 57 .(109) We did not find any 
difference in spleen size between JAK2V617 positive and JAK2WT ET, similar to other 
studies.(104,105) 
One patient lacking the JAK2 mutation had non ST elevated myocardial infarction. 
We found a significant association between the platelet count and the JAK2 mutation status.  
JAK2WT patients had higher platelet counts (1052 vs 777 x10³/µl , P value =.02). Kittur et al 
noticed a similar finding in 176 patients with ET. (110) However, such an association was not 
reported by Vytrva et al (103) and Campbell et al . (105) 
Although our JAK2V617 positive ET patients had a higher haemoglobin and total WBC count 
similar to other reports, this did not reach statistical significance. ET is associated with 
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sequestration of platelets in the spleen as there is no extramedullary haemopoiesis except 
in the late stage. 
The bone marrow trephine biopsies showed a statistically significant difference between 
JAK2V617 positive and JAK2WT ET only with regard to the presence of large clusters of 
megakaryocytes in JAK2WT (58% versus 92%, P value = .048).This feature has not been 
described by Vytrva et al. (103), Campbell et al(104) and Nataliya Vytrva et al (103) have 
reported a statistically significant increase in granulocytic precursors in those with and 
without the mutation. Although increase in granulocytic precursors was seen in 25% of 
those with the JAK2 mutation as compared to 15% of those lacking the mutation, this 
difference was not statistically significant in our study. 
Cytogenetics 
Cytogenetic aberrations are more common in PMF than in ET. Cytogenetic analysis is 
difficult in PMF because the marrow often does not yield an aspirate. Karyotyping may then 
have to be done on peripheral blood. The abnormalities are the same in both conditions. 
There are no specific abnormalities associated with either disorder reflecting a similar 
pathogenesis. 
The main role of cytogenetics and FISH in these diseases is to demonstrate the presence of a 
clonal abnormality and to exclude the presence of the t(9;22). The role of cytogenetics in 
the prognostication of MPN is not as well defined as for the other haematological 
neoplasms. Tefferi et al suggest that abnormalities such as trisomy 8 and the deletion 12p 
are associated with a poor prognosis in PMF while the deletions 20q and 13q did not have a 
prognostic impact. (112). Chromosomal aberrations may be found in 40-50% of PMF. As the 
disease progresses, structural abnormalities resulting in gain of chromosome 1q and 
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abnormalities of chromosome 7 may be seen. The karyotypes are usually associated with 
chromosomal imbalance.  The common changes such as trisomies 8 and 9, deletions 13q 
and 20q and gain of 1q account for 80% of abnormal karyotypes. (113,114) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
Summary and conclusions 
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We have described the histological features of 107 primary myelofibrosis (PMF) and 27  
essential thrombocythaemia (ET) over a period of  five years. 
We have devised a scoring system to classify these  condition and to attempt to identify the 
histological differences between the early (pre-fibrotic) phase of PMF and ET which show 
considerable overlap. 
We have also recorded the clinical and laboratory parameters including JAK2 mutation 
status and results of FISH for BCR -ABL when available. 
The majority of our patients were 
 Males (71%) 
 Adults ( median age 50 years: range 5-72years ) 
There were 94 cases of PMF excluding the 13 in the prefibrotic phase. 
The following histological features were seen in more than (80%) of PMF analysed 
 Megakaryocytes in paratrabecular location 
 Increased number of megakaryocytes 
 Large megakaryocytes 
 Hypolobate bulbous cloud like megakaryocytes 
 Hyperchromatic dysplastic megakaryocytes 
 Sinusoidal ectasia 
 Intrasinusoidal haematopoiesis 
All 13 cases in the Prefibrotic phase of PMF showed the following histological 
features: 
 Increase in granulocytic precursors 
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 Increased  numbers of  megakaryocytes 
 Large megakaryocytes 
 Paratrabecular location of megakaryocytes. 
 Loose clusters of megakaryocytes 
 Absence of  intrasinusoidal haematopoiesis 
 Reticulin grade MF1 (scored as 0). 
All 27 ET showed 
 Increased  numbers of megakaryocytes 
 Large megakaryocyte with hyperlobate staghorn type nuclei 
 Clustering of megakaryocytes with both small and loose clusters 
 Absence of myeloid left shift, sinusoidal ectasia and intrasinusoidal 
haematopoiesis 
 Reticulin grade MF0 or MF01. 
 The most important diagnostic criterion of PMF was the reticulin grade. 
 MF3 was seen in 97% of PMF while only 3% had MF2. 
 MF0 - MF1 was seen in ET and prefibrotic phase of PMF. 
 There were several statistically significant differences between ET and the Prefibrotic 
phase of PMF. 
Cellular and vascular changes 
The statistically significant features in favour of prefibrotic phase of PMF, not seen in  any of 
the 27 cases of ET were 
 Left shift in myeloid lineage 
 Decreased numbers of erythroid cells 
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 Small megakaryocytes 
 Sinusoidal ectasia 
Another very significant finding in favour of Pre-fibrotic phase of PMF 
 Paratrabecular  megakaryocytes 
Findings which were seen more commonly in the prefibrotic phase of PMF than in ET were: 
 Increased cellularity 
 Myeloid hyperplasia 
 Hyperchromatic dysplastic megakaryocyte nuclei 
 Naked megakaryocyte nuclei 
 Dense clusters of megakaryocytes 
A finding seen more commonly in ET than in the prefibrotic phase of PMF was: 
 Hyperlobate staghorn megakaryocyte nuclei 
Reticulin 
Reticulin was graded as MF1 in all 13 prefibrotic phase of PMF and in the majority  of ET, 
showing that reticulin pattern does not distinguish between these two conditions. 
However, no single feature including reticulin grade can be used to differentiate between 
these two conditions as there is considerable overlap in the histological features. 
We devised a scoring system based on 16 histological features to ensure a systematic 
assessment. 
 Each   parameter was scored from 0-2 to obtain scores in the   range of  5-21 . 
 Scores for ET were 5-9, while the prefibrotic phase of PMF had scores of 12-17. 
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 We did not have any biopsies with scores of 10-11.  It would be difficult to unequivocally 
distinguish between ET and prefibrotic phase of PMF if the biopsy score is in this range. 
 
JAK2 mutation status 
The JAK2 V617 mutation was present in 60 of the 98 patients tested. There did not 
appear to be statistically significant differences in histological findings between JAK2V617 
PMF and JAK2WT PMF. 
 With regard to laboratory parameters only the mean haemoglobin at presentation 
showed a statistically significant difference between the JAK2V617 positive PMF and 
JAK2WT PMF. 
 JAK2WT ET showed a higher platelet count and the presence of large clusters of 
megakaryocytes in comparison to JAK2 V617positive ET. 
 
 
 
 
 
           
 
 
 
 
Limitation 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 This is a purely descriptive study. Although we have adequate laboratory and 
clinical data , we do not have follow up details. 
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APPENDIX- 1 
 
PROFORMA FOR ASSESSMENT OF   PMF / ET. 
 
UID number 
 
Biopsy no: 
 
Hospital No                                  Age:                Sex:                       Date 
 
Haemoglobin:             g / dL     TC:             ×10 
3
 / µ L   Platelet  count :               /10 
3
 / µL 
 
DC: N          %,  E      %,  B       %,  L      %, M       %,  Blasts        %,   NRBCs:      /100 
 
 
Blood picture 
 Tear drop cells 
 Poikilocytosis, 
 Pseudo Pelger Huet cells 
 Platelet  morphology 
 
 
 
Bone marrow  Findings Trephine Aspirate 
1) Length  of cores 
 
  
2) Number of intertrabaecular spaces  
3) Increased cellularity 
Absent(00)/Present (01) 
 
4) Granulocyte precursors 
Hyperplasia(1)/ hypoplasia(0) /normal(0) 
/decreased(2) 
 
 
5) Left-shift (Absent 00/Present01)  
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6) Erythroids 
Hyperplasia(1) / normal(0) /decreased(2) 
 
 
7)Megakaryopoiesis       
Histotopography/increased number(1) 
/normal(0)/decreased(2) 
 
 
8)Histotopography 
Location: Paratrabecular(1) 
 
Perisinusoidal(00) 
9)Size 
 
Small(2)  
Increased (Large Size) (1)  
Normal Size(0)   
10)Nuclear features   
Hypolobulation(bulbous/cloud-like) (1)   
Hyperlobulation (staghorn-like) (1)   
Hyperchromatic dysplastic nuclei(1)   
Naked nuclei(1)   
11)Cluster formation   
Small clusters(> 3)  megakaryocytes(1)   
Large clusters (> 7)(2)   
12)Cluster density and number   
Dense clusters(1)   
Number of dense clusters   
Loose clusters (0)   
Number of loose clusters   
13)Sinusoidal ectasia (1)   
14)Intrasinusoidal  haematopoiesis(1)   
15)  Reticulin (WHO 2008 grading)   
MF0: Scattered linear reticulin(0) 
 
  
MF1:  Loose network, many 
intersections, perivascular areas.(0) 
 
 
 
 
 
 
MF2: Diffuse, dense, focal bundles of 
collagen/osteosclerosis.(1) 
  
 
MF3: Diffuse, dense, extensive 
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intersections, coarse collagen, 
Osteosclerosis(1) 
16) Cytogenetic analysis 
Available/ not available 
List of abnormalities 
  
 
17)FISH for BCR/ABL1 fusion 
Present/Absent/Not available 
 
  
18)JAK2 mutation status: 
Present/Absent/Not available 
 
  
19) Serum LDH levels 
Present (levels)/Not available 
  
 
*Trephine biopsy only 
** Prefibrotic and fibrotic phases 
( ) Number in the bracket indicates score. 
 
 
 
 
20) Clinical findings 
 
21) Splenomegaly:  Present     Size in cm ------------ /absent  /  Not available 
 
22) Constitutional symptoms:  Present /   absent / Not available 
 
a) Drenching night sweats 
b) Weight loss>10%over six months 
c) Unexplained Fever (>37.5°C) 
d) Diffuse bone pains 
 
For ET (Vascular occlusion, haemorrhage such or any thrombotic episode such as 
splenic or portal vein thrombosis) 
 
23) IPSS score 
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                                                       APPENDIX 2 
Table :1 Histological features of bone marrow trephine biopsies in JAK2V617 positive and JAK2WT myelofibrosis(MF) 
HISTOLOGICAL DIAGNOSIS PMF, n=6 JAK2V617positive 
N=43 
JAK2 Wild 
type, n=24 
P value 
1)Increased Overall Cellularity, Absent 12(27.91) 06(25) 0.797 
Present 31(72.09) 18(75)  
2)Granulocyte Precursors Increased 11(25.58) 05(20.83) 0.662 
Normal 32(74.42) 19(79.17)  
3)Left shift  number Absent 21(48.84) 10(41.67) 0.572 
Present 22(51.16) 14(58.33)  
4)Erythroid cellularity (number) Normal 14(32.56) 05(20.83)  
Increased 01(2.33) 2(8.33)  
Decreased 28(65.12) 17(70.83) .35 
5)Megakaryopoiesis Normal 01 01 .693 
Increased 42(97.67) 23(95.83)  
Decreased 00 00  
6)Megakaryocyte location Paratrabaecular 43(100) 24(100)  
Perisinusoidal(Normal) 43(100) 24(100)  
7)Type of megakaryocytes Small Absent 24(55.81) 17(70.83) .328 
Present 19(44.19) 07(29.17)  
Large Absent 05(11.63) 02(8.33) .673 
Present 38(88.37) 22(91.67)  
 Normal Absent 02(4.65) 00 .283 
Present 41(95.35) 24(100)  
8)Hypolobate cloud like 
megakaryocyte nuclei 
Absent 05(11.63) 02(8.33) .673 
Present 38(88.37) 22(91.67)  
9)Hyperlobate , giant and 
staghorn megakaryocytic nuclei 
Absent 30(69.77) 15(62.50) .54 
Present 13(30.23) 09(37.50)  
10)Hyperchromatic dysplastic 
nuclei 
Absent 00 02(8.33) 0.056 
Present 43(100) 22(91.67)  
11)Naked nuclei Absent 18 10 0.98 
Present 25 14  
12)Type of megakaryocyte 
clusters 
Small Absent 02 02 .05 
Present 43(100) 22(91.66)  
Large Absent 09(20.93) 5(20.83) .993 
Present 34(79.07) 19(79.17)  
13)Density of Megakarocytes 
clusters 
Loose Absent 03(6.98) 03(12.50) .448 
Present 40(93.02) 21(87.50)  
Dense Absent 11(25.58) 09(37.50) .307 
Present 32(74.42) 15(62.50)  
Number of large megakaryocyte 
clusters/mm(median) 
 .11 .20 .43 
Number of small megakaryocyte 
clusters/mm(median) 
 .58 .44 .88 
14)Sinusoidal ectasia Absent 03(6.98) 03(12.50) .448 
Present 40(93.02) 21(87.50)  
15)Intra sinusoidal 
haematopoiesis 
Absent 4(9.30) 05(20.83) .184 
Present 39(90.70) 19(79.17)  
 MF2 01(2.33) 00  
 MF3 42(97.67) 24(100) .452 
16)Reticulin score 0 0 0  
1 43(100) 24(100)  
Total Score ( median, range)  15(12-21) 16(13-21)  
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                                                       Appendix 3 
 
Hematologic and clinical data in JAK2V617 positive prefibrotic phase of PMF 
 
Prefibrotic phase of PMF, n=5 JAK2V617POSITIVE 
Number of cases 05 
Age at diagnosis,(median) Median 52, range -5-69 
Sex 
Male 4(80) 
Female 1(20) 
Laboratory findings Range Mean Median 
Haemoglobin (g/dl) at diagnosis 8-17 12  
Leucocyte count x10³/ µl 
at diagnosis 
6.7-67.1  26 
Platelet count x 10³/µl 
at diagnosis. 
328-712  521 
LDH IU/l 850,656-1231 850 656-1231 
Splenomegaly Absent 02 
No of cases with 
splenomegaly 
03(60%) 
mean size in cm 15.45  cms 
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 Appendix -4 
Comparison of myelofibrosis and its Prefibrotic phase – histological findings 
        
  PMF , n=94 Prefibrotic phase, 
n=13 
P value 
n % n %  
Increased cellularity Present 67 71 13 100 .025 
Granulocyte Precursors Increased 43 46 13 100 .025 
Myeloid left shift Absent 51 54 06 43  
Present 43 46 07 54 .583 
Erythroid cellularity (number) Normal 26 28 05 38 .615 
Decreased 65 69 08 61  
Increased 03 03 13 100  
Megakaryopoiesis Increased 89 95 13 100 .394 
Megakaryocyte location Paratrabecular 92 98 13 100 .595 
Normal perisinusoidal 94 100 13 100 .709 
Type of megakaryocytes Small 39 41 05 38 .835 
Large 81 86 13 100 .153 
Normal 92 98 13 100 .595 
Megakaryocyte nuclei 
Hypolobate bulbous cloud like 
nuclei 
Present 85 90 13 100 .496 
Hyperlobate , giant and 
staghorn megakaryocytic nuclei 
Absent 59 63 04 31  
Present 35 37 09 69 .028 
Hyperchromatic dysplastic nuclei Absent 6 6 02 15  
Present 88 94 11 85 .247 
Naked nuclei Absent 44 47 07 54  
 Present 50 53 06 46 .634 
Megakaryocyte clusters Small 92 98 13 100 .595 
 Large 71 75 11 84 .468 
 Loose 88 94 13 100 .348 
 Dense 66 70 08 61 .615 
Sinusoids 
Sinusoidal ectasia Absent 8 8 9   
Present 86 92 4 69 <.0001 
Intra sinusoidal haematopoiesis Absent 12 13 13 100  
Present 82 87 0 0 <.0001 
Reticulin      
Reticulin grade MF0 - -   
 MF1 - - 13 100  
 MF2 3 3 -   
 MF3 91 97 -   
Reticulin score 0    
1    
Scores 
CMC score  15,12-21 15,12-17  
Brousseau  score ( median, range)   8,6-10  
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 Appendix 5 
Histological features of bone marrow trephine biopsies in JAK2V617 positive 
prefibrotic MF 
 
 
 
 
 
 
 
 
HISTOLOGICAL DIAGNOSIS PMF, n=6 JAK2V617positive 
Increased cellularity Present 05(100) 
Granulocyte Precursors Increased 05(100) 
Left shift  number Absent 01(20%) 
Present 04(80%) 
Erythroid cellularity (number) Normal 03(60%) 
Decreased 02(40%) 
Increased 05(100) 
Megakaryocyte location Paratrabaecular 05(100) 
Perisinusoidal 05(100) 
Type of megakaryocytes Small Present 02(40) 
Large Present 05(100) 
Normal Present 05(100) 
Hyperlobate , giant and staghorn 
megakaryocytic nuclei 
Absent 02(40) 
Present 03(60) 
Hyperchromatic dysplastic nuclei Absent 02(40) 
Present 03(60) 
Naked nuclei Absent 02(40) 
Present 03(60) 
Type of megakaryocyte clusters Small Present 05(100) 
 Large Present 05(100) 
Loose Present 05(100) 
Dense Absent 02(40%) 
Present 03(60%) 
Number of large megakaryocyte 
clusters/mm(median) 
 0.06 
Number of small 
megakaryocyte clusters/mm(median) 
 .76 
Sinusoidal ectasia Absent 03(60) 
Present 02(40) 
Intra sinusoidal haematopoiesis Absent 05(100) 
Present 00 
Reticulin MF0 00 
 MF1 05(100) 
 MF2 00 
 MF3 00 
Reticulin score 0 05(100) 
1 00 
TS ( median, range)  15,12-17 
Maud Brousseau, et al score 
( median, range) 
 07, 6-10 
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Appendix 6 - Comparison of JAK2V617 positive and JAK2WT ET - clinical and 
laboratory data 
 
 
Parameter JAK2V617 POSITIVE, n-
12 
JAK2 WILD TYPE , n=13 P value 
Number of cases 12 13  
Median age at diagnosis 40 39  
Sex  
Males 5(42%) 9(69%)  
Females 7(58%) 4(31%)  
Spleen size  
No splenomegaly 11 12  
Splenomegaly present in 1 (size 10.6 cm) 1 (size 12.7 cm)  
Thrombotic events  
Present (see text) 4 1  
Laboratory data 
Haemoglobin (g/dl) 10.8-15.5, mean 13 g/dl 9.4-15.3, mean 12.9 g/dl .91 
Leucocyte count x10³/µl 7.1-48.2  median  16 5.5-18.9  Median 10 .09 
Platelet count x10³/µl 454 -1484  Median 777 594-2580  Median 1052 .02 
    
Peripheral smear    
Abnormal 4 9  
Thrombocytosis on smear 2 8  
Giant platelets on smear 2 1  
Circulating blasts (%) 0 0  
Serum LDH  
Range IU/L 428.7-1129 (median 705.8) 319-1402 (median 581) .17 
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Appendix 7:  Comparison of JAK2V617 positive and JAK2WT ET - Histological 
features of bone marrow trephine 
 
HISTOLOGICAL FEATURE  JAK2V617positive 
, n-12 
JAK2 Wild type 
n-13 
P 
value 
Increased  cellularity Absent 03(25) 04(25) 1.0 
Present 09(75) 09(75)  
Granulocyte Precursors Increased 03(25) 02(15.38) .645 
Normal 09(75) 11(84.61)  
Myeloid left shift Absent 12 13  
Erythroid cellularity Normal 09 12  
Increased 03(25%) 01(7.6%) .322 
Megakaryocyte location Paratrabecular 5(41.67) 3(23.08) 0.411 
Perisinusoidal 12(100) 13(100)  
Type of Megakarocytes Small Absent 12(100) 13(100)  
 Present 12(100) 13(100)  
 Normal Absent 1(8.33) 1(7.69) .95 
Present 11(91.67) 12(92.31)  
Megakaryocyte nuclei 
Hypolobate cloud like 
megakaryocyte nuclei 
Absent 2(16.67) 3(23.08) .68 
Present 10(83.33) 10(76.92)  
Present 12(100) 13(100)  
Hyperchromatic dysplastic nuclei Absent 11(91.67) 12(92.31) 1.00 
Present 1(8.33) 1(7.69)  
Naked nuclei Absent 10(83.33) 10(76.92) 1.00 
Present 2(16.67) 3(23.08)  
Megakaryocyte clusters      
Size of clusters Small Absent 0 0  
Present 12(100) 13  
Large Absent 5(41.67) 1(7.69) .047 
Present 7(58.33) 12(92.31)  
Density of clusters Loose Absent 0 0  
Present 12(100) 13(100)  
Dense Absent 10(83.33) 12(92.30)  
Present 2(16.67) 1(7.69) .59 
Sinusoids 
Sinusoidal ectasia Absent 12(100) 13(100)  
Intra sinusoidal haematopoiesis Absent 12 13  
Reticulin     
Grade MF0 02(16.67) 03(23.08) .198 
 MF1 10(83.33) 10(76.92)  
 MF2 and MF3 - -  
Reticulin score 0 12(100) 13(100  
Scoring 
CMC score  5-9 ( median 8 ) 6-9 (median 8 )  
Brosseau  1-4 ( median 2 ) 2,1-4( median 2)  
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Appendix 8 
Comparison  of clinical and laboratory data in JAK2 positive cases 
 
 JAK2V617 positive ET, n=12 JAK2V617 positive Prefibrotic phase of PMF, 
n=13 
Number 12 05 
Male(number ,%) 05(41.67) 04(80) 
Female(number , %) 07(58.33) 01(20) 
Age (years, median) 40 56 
Haemoglobin(g/l)- 
(mean , range) 
12.85,10.8- 15.5 11.5,8-17 
WBC count x10³/µl 
(median, range) 
15.950,7.1-48.2 26,6.7-67.1 
Platelet count x10³/µl 
(median , range) 
777, 
454-1484 
521, 
328-712 
 
Circulating blasts, number, %, range 00 00 
Peripheral blood 
films 
Abnormal 00 02(40%),LEBP 
Normal 12(100) 03 
Splenomegaly Absent 11 02 
Present) 01(8.33) 03(60%) 
spleen size in 
cm (mean) 
10.6 cms 15.45 cms 
No of cases for which LDH values 
were present    (number,%) 
07,58.33 05, 100 
(LDH IU/l) ((median, range) 
 
705.8,428.7-1129 850,656-1231 
Past arterial thrombosis, number (%) 00 00 
Past venous thrombosis , number(%) 04(36) 00 
Major bleeding /haemorrhage, 
number(%) 
00 00 
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                                               Appendix -9 
                                                          
                              Karyotype  in PMF, Preffibrotic phase of PMF and ET 
 Karyotype done in Abnormal Karyotypes in   Karyotypes  
PMF 56 23 1)deletion 20q (6 patients ) 
2)deletion 13q(3 patients)  
and trisomy 8 (3 Patients). 
3)Trisomy 9 and loss of 
chromosome 7q was seen in 
(2 patients) because of a 
partial deletion or an 
unbalanced t(1;7) which 
resulted in monosomy for 7q 
and trisomy for 1q. 
4) Deletion 12p was seen in 
(one patient). 
 
Prefibrotic phase 
of PMF 
04 02 One had 47 chromosomes 
due to trisomy 9 and a partial 
deletion of the long (q) arm of 
chromosome 7 and the other 
showed an unusual  
 t (4;11)(q25-q27; p13-15). 
 
ET 06 Nil 46XX,46XY 
 
